0001262463-23-000074.txt : 20230830 0001262463-23-000074.hdr.sgml : 20230830 20230830160234 ACCESSION NUMBER: 0001262463-23-000074 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 40 CONFORMED PERIOD OF REPORT: 20230531 FILED AS OF DATE: 20230830 DATE AS OF CHANGE: 20230830 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PREAXIA HEALTH CARE PAYMENT SYSTEMS INC. CENTRAL INDEX KEY: 0001350156 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-HOME FURNITURE, FURNISHINGS & EQUIPMENT STORES [5700] IRS NUMBER: 204395271 STATE OF INCORPORATION: NV FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-52365 FILM NUMBER: 231225240 BUSINESS ADDRESS: STREET 1: #207, 1410 ? 11TH AVENUE SW CITY: CALGARY STATE: A0 ZIP: T3C 0M8 BUSINESS PHONE: 306-653-5080 MAIL ADDRESS: STREET 1: C/O LIZ?E GAUTHIER CGA STREET 2: 202 ? 3550 TAYLOR STREET E CITY: SASKATOON STATE: A9 ZIP: S7H 5H9 FORMER COMPANY: FORMER CONFORMED NAME: SUN WORLD PARTNERS INC DATE OF NAME CHANGE: 20060119 10-K 1 paxh53123.htm FORM 10-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K

(Mark One)

[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended May 31, 2023

☐ [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________ to________________

Commission file number 000-53490

PREAXIA HEALTH CARE PAYMENT SYSTEMS INC.
(Exact name of registrant as specified in its charter)

Nevada	20-4395271
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

PO Box 34075 Westbrook PO, 1610-37th Street S.W., Calgary, Alberta T3C 3W2

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code (403) 850-4120

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

None

N/A

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, $0.001 par value
(Title of class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes [ ] No [X]

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
Yes [ ] No [X]

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes [X] No [ ] No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes [ X ] No [ ]

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [X ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]		Accelerated filer [ ]
Non-accelerated filer [X]		Smaller reporting company [X]
		Emerging growth company☐ [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
Yes [ ] No [X]

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. [ ]

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter. Approximately $602,725 on November 30, 2022.

(APPLICABLE ONLY TO CORPORATE REGISTRANTS)

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date:

19,767,698 shares of common stock as of August 30, 2023

DOCUMENTS INCORPORATED BY REFERENCE

Not Applicable.

TABLE OF CONTENTS

PART I	4

FORWARD-LOOKING STATEMENTS.	4

ITEM 1. BUSINESS	4

ITEM 1A. RISK FACTORS	6

ITEM 1B. UNRESOLVED STAFF COMMENTS	7

ITEM 2. PROPERTIES	7

ITEM 3. LEGAL PROCEEDINGS	7

ITEM 4. MINE SAFETY DISCLOSURES	7

PART II	7

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES	7

ITEM 6. SELECTED FINANCIAL DATA	8

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	8

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	11

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA	11

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	12

ITEM 9A. CONTROLS AND PROCEDURES	12

ITEM 9B. OTHER INFORMATION	12

PART III	12

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE	12

ITEM 11. EXECUTIVE COMPENSATION	16

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	18

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE	18

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES	19

PART IV	19

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES	19

ITEM 16. FORM 10-K SUMMARY	20

SIGNATURES	21

PART I

FORWARD-LOOKING STATEMENTS.

This annual report contains forward-looking statements. Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “intend,” “expect,”, “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, including uncertainties and other factors, which may cause our or our industry’s actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. These risks and uncertainties include: a continued downturn in international economic conditions; any adverse occurrence with respect to the development or marketing of our product; any adverse occurrence with respect to any of our licensing agreements; our ability to successfully bring products to market; product development or other initiatives by our competitors; fluctuations in the availability and cost of materials required to produce our products; any adverse occurrence with respect to distribution of our products; potential negative financial impact from claims, lawsuits and other legal proceedings or challenges; and other factors beyond our control.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity or performance. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

As used in this annual report, the terms “we,” “us,” “our,” the “Corporation,” and “PreAxia” mean PreAxia Health Care Payment Systems Inc. and our and its wholly owned subsidiaries (i) PreAxia Health Care Payment Systems Inc., incorporated pursuant to the laws of the Province of Alberta on January 28, 2008 (ii) PreAxia Canada Inc., incorporated pursuant to the laws of the Province of Alberta on January 28, 2008 and (iii) PreAxia Health Care Payment Ltd., incorporated pursuant to the laws of the Province of Alberta on November 26, 2015 (collectively, the “Subsidiaries”), unless the context clearly requires otherwise. Unless otherwise stated, “$” refers to United States dollars.

ITEM 1. BUSINESS

Corporate Overview

PreAxia Health Care Payment Systems Inc. (the “Company” or “PreAxia”) was incorporated on April 3, 2000 in the State of Nevada.

The Company primarily undertakes its operations through its wholly-owned subsidiary, PreAxia Health Care Payment Limited (“PreAxia Payment”). PreAxia Payment was incorporated pursuant to the laws of the Province of Alberta on November 26, 2015.

General Overview

PreAxia Payment is a company which intends to deliver a comprehensive suite of solutions and services directed at the emerging health payment market, specifically the opportunities tied to the growth of health spending accounts (“HSA”). There is a rapid shift in healthcare traditional payment models to consumer-directed healthcare that is creating significant opportunities for financial services and insurance industries to deliver new dynamic products to this emerging market.

Spawned by the need to address escalating health care costs, changes in the regulatory environment and the growing consumer desire for greater participation in the management of their health benefits, the boundaries between health care and the financial services industries are becoming increasingly blurred. With the trend towards self-directed health payment solutions and the growing demand for faster, easier and more convenient benefit services, the insurance and benefits industries are banking on HSA medical payments being their next big growth conduit. Studies suggest that HSAs in the US reached $122.8 billion in assets in 2023 and 33.9 million consumers in 2022, an increase of 11% of assets over the prior period. This coupled with the continued growth of the Canadian group insurance industry illustrates the emerging opportunity for innovative health payment services. We intend to initially launch our products in Canada. We believe that Canadian businesses are embracing a new healthcare financing vehicle to provide greater value to employees, increase profitability and get more return from their investment. We intend to provide them with services to capture this market opportunity.

Description of Health Spending Account (“HSA”)

An HSA is a uniquely designed account established exclusively and specifically for the purpose of health care spending. An employer deposits funds into a special account for the employee. These funds can be used to pay for eligible medical and related health care expenses for the employee and their dependents. HSAs provide employers and employees with greater control in both the amount of funds invested and how these funds are used.

Services and infrastructure provided by PreAxia enable organizations and individuals to eliminate all paper involved in the management of these accounts and benefit through savings in time and money.

The PreAxia platform for processing and managing accounts, including cardholder and customer account management, reconciliation and financial settlement, and customer reporting is fully operational.

Over time, the Company will evaluate opportunities for forms of virtual banking and PayPal-type services. One opportunity seen as particularly relevant to the health care market is to offer instant issuing services that enable corporations to issue and fund Pre-Paid Interac or credit card services to beneficiaries in real time. If implemented, the beneficiary will most likely select a personal identification number (“PIN”) using a PIN and card activation terminal, thus gaining instant access to funds that can be reloaded. This consideration would require development of software systems for the issuing of health payment cards and financial transaction processing services that would be fully managed by a data center.

Matching of consumers in need of health care products or services with providers is another area PreAxia intends to evaluate. Consumers managing their health care dollars through an online system will find convenience in seeking out health care professionals and services through the same system.

Distribution Methods and Marketing Strategy

PreAxia operates on a Cloud Computing Platform that makes it accessible to anyone with a personal computer and Internet access. The preliminary market for PreAxia’s HSA Management Solution is small and medium sized companies that are not currently well served by the current group benefits model. The financial benefits of the PreAxia business model, however, are also relevant to larger employers and we believe that these larger employers will migrate to the PreAxia product over time.

PreAxia’s marketing strategy is to promote its existing platform direct to consumers and businesses, and to the groups that most need access to it; independent brokers, financial advisors and small to medium sized businesses. Brokers should see PreAxia as a superior method of promoting and supporting HSAs that allow them to earn above average commission rates on invested funds. Financial advisors should see PreAxia in a similar way as brokers except that there is the additional benefit of tax reduction. Small to medium sized businesses, which are expected to drive the growth in business, should see PreAxia as offering financial savings to the company and to employees by offering personal health care benefits through an HSA, along with the same conveniences they have come to expect from other services they currently utilize over the Internet. It is expected that the group benefits market will subsequently follow as they too realize the advantages of PreAxia over their current HSA offerings. PreAxia has begun and will continue to seek opportunities with lead customers and alliance partners to establish reference-able, high-profile implementations and market-leading, early-adopter firms for further developing innovative products and services. The Company intends to design solutions targeted towards corporate financial management, financial risk, audit management and cash management while targeting product/service management as a support to financial management.

We anticipate that the prime target for services will be small to medium sized organizations that are not adequately served by the current insurance and group benefits offerings. These organizations should realize significant benefits in both cost and time savings by utilization of PreAxia technology while providing their employees with an increased level of benefits.

PreAxia intends to achieve service volume and the associated economies of scale through marketing directly to select target customers that provide the necessary transaction volumes, through market specific channel partners and through an education based public relations strategy geared to the small to mid-sized employers including the brokers and financial advisors utilized by these businesses. The channel strategy is supported in the solution design, as multiple channel partners may require custom pricing and compensation.

It is our Company’s intention that brokers and financial advisors will aggressively promote their PreAxia supported HSA offerings due to the quality of product, higher margins and because of the non-competitive relationship with PreAxia.

PreAxia has identified the following “channels” through which it will target prime end market customers:

☐

Independent brokers that sell, or desire to sell, Health Spending Accounts

☐

Financial advisors who manage funds and advise on tax saving strategies for individuals and corporations

☐

Accountants and bookkeepers who regularly advise businesses on financial and operational matters

☐

Benefits managers/adjudicators, including insurance, health or outsourced government benefits processors that manage benefits disbursement

☐

Issuer banks, including partner banks that enable the issuance of Health Cards and/or sell insurance products

☐

Application providers, including software manufacturers selling into the target vertical markets

☐

Professional services, including consulting, development and implementation companies serving the target vertical markets

PreAxia intends to establish several key customer reference accounts, channel marketing partners and technology alliances. These corporate relationships are relevant to advancing our company’s goals in 2022 and beyond for achieving a prime position in the Canadian marketplace and establishing a solid service foundation.

Competitive Business Conditions and our Company’s Competitive Position in the Industry and Methods of Competition

PreAxia intends to offer a combination of products and services in its solution. However, there are other providers of components or versions of the Health Spending Accounts in the marketplace. Our approach is to provide a high value added and robust capability within specific target markets, rather than the “one size fits all” and mass volume approach of the larger companies in the Canadian and international market. This is consistent with the PreAxia platform which has been designed for expansion in the United States and internationally. The following are some of the leading providers of products and services that are or may be potential competitors in PreAxia’s target markets:

Benecaid has become a leading provider of Health Spending Accounts in Canada by offering an easy to understand product through brokers and also directly through the company.

Olympia Benefits has become a leading provider of Health Spending Accounts in Canada by offering a “Cost Plus” version of HSAs that has become popular in the marketplace.

QuickCard is a provider of Health Spending Accounts and group insurance products. They are partially differentiated from competitors by virtue of a “credit type card” that is used to pay for qualified health products and services.

· League, which operates in Canada and the US, offers a range of health benefit services including Health Spending Accounts.

Most major insurance companies offer some version of HSAs to their customers.

Many brokers have created HSA products for their clients.

Many accounting and financial services firms have created their own HSA products to offer to their clients.

US and International Markets

HealthEquity, a publicly listed company offering HSAs in the USA, manages over $22 billion in deposits. It is one of the largest dedicated health account custodians in the USA and serves more than 12 million accounts owned by individuals at more than 24,000 companies across the country.

HSA Bank, a division of Webster Bank, offers Health Spending Accounts and related offerings to the consumer-directed healthcare industry.

Fidelity Investments offers a Health Spending Account to businesses as a means of controlling costs while providing employee health benefits.

Intellectual Property and Patent Protection

At present, PreAxia does not have any pending or registered patents or any trademarks.

Research and Development

For the year ended May 31, 2023 and 2022, we incurred $6,528 and $25,642 in research and development expenses.

Employees

PreAxia has one full-time consultant, our President, Mr. Tom Zapatinas effective September 1, 2011. We anticipate that we will hire additional key staff throughout 2023 and 2024 in areas of administration/accounting, business development, operations, sales/marketing and research/development.

ITEM 1A. RISK FACTORS

Not applicable to smaller reporting companies.

ITEM 1B. UNRESOLVED STAFF COMMENTS

Not applicable.

ITEM 2. PROPERTIES

Although much of the research and development and the building of our system have been completed, our Calgary office closed during the 2017 fiscal year and we presently operate out of remote employment sites.

ITEM 3. LEGAL PROCEEDINGS

We know of no material, active or pending legal proceedings against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

Our common stock is quoted on the OTC Markets Pink Sheets under the symbol PAXH.

Following is a report of high and low bid prices for each quarterly period for the years ended May 31, 2023 and 2022.

Quarter Ended	High	Low
05/31/2023	$0.0565	$0.0565
02/28/2023	$0.45	$0.0565
11/30/2022	$0.0565	$0.0565
08/31/2022	$0.25	$0.0565
05/31/2022	$0.10	$0.10
02/28/2022	$0.75	$0.09
11/30/2021	$0.10	$0.10
08/31/2021	$0.50	$0.10

Holders of Our Common Stock

As of August 30, 2023, there were 83 holders of record of our common stock and 19,767,698 shares of common stock outstanding.

There is currently only one class of common stock with one vote per share.

Pacific Stock Transfer Company of 6725 Via Austin Parkway, Suite 300, Las Vegas, Nevada 89119, is the registrar and transfer agent for our common shares.

Dividends

We have not declared or paid dividends on shares of our common stock and we do not expect to declare or pay dividends on shares of our common stock for the foreseeable future. We intend to retain earnings, if any, to finance the development and expansion of our business. Our future dividend policy will be subject to the discretion of our board of directors and will depend upon our future earnings, if any, our financial condition, and other factors deemed relevant by the board.

Equity Compensation Plans

We adopted and approved our current stock option plan on January 28, 2010. The following table provides a summary of the number of options granted under our stock option plan, the weighted average exercise price and the number of options remaining available for issuance all as of May 31, 2023.

	Number of securities to be issued upon exercise of outstanding options, warrants and rights	Weighted-average exercise price of outstanding options, warrants and rights	Number of securities remaining available for future issuance under equity compensation plans
Equity compensation plans approved by security holders	None	N/A	2,000,000
Equity compensation plans not approved by security holders	None	N/A	None
Total	None	N/A	2,000,000

Recent Sales of Unregistered Securities

We have not sold any equity securities that were not registered under the Securities Act of 1933 that were not previously reported in a quarterly report on Form 10-Q or in a current report on Form 8-K during the fiscal year ended May 31, 2023.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

We did not purchase any of our shares of common stock or other securities during our fiscal years ended May 31, 2023 or 2022.

ITEM 6. SELECTED FINANCIAL DATA

Not Applicable.

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

General Overview

Corporate Overview

PreAxia Health Care Payment Systems Inc. (the “Company” or “PreAxia”) was incorporated on April 3, 2000 in the State of Nevada.

General Overview

Spawned by the need to address escalating health care costs, changes in the regulatory environment and the growing consumer desire for greater participation in the management of their health benefits, the boundaries between health care and the financial services industries are becoming increasingly blurred. With the trend towards self-directed health payment solutions and the growing demand for faster, easier and more convenient benefit services, the insurance and benefits industries are banking on HSA medical payments being their next big growth conduit. Studies suggest that HSAs in the US reached $122.8 billion in assets in 2023 and 33.9 million consumers in 2022, an increase of more than 11% of assets over the prior year. This coupled with the continued growth of the Canadian group insurance industry illustrates the emerging opportunity for innovative health payment services. We intend to initially launch our products in Canada. We believe that Canadian businesses are embracing a new healthcare financing vehicle to provide greater value to employees, increase profitability and get more return from their investment. We intend to provide them with services to capture this market opportunity.

Plan of Operation

Over the next twelve months, we plan to:

	(a)	Raise additional capital to execute our business plans;

	(b)	Penetrate the health care processing markets in Canada, the United States and worldwide, by continuing to develop innovative health care processing products and services;

	(c)	Build up a network of strategic alliances with several types of health insurance companies, governments and other alliances in various vertical markets, and;

	(d)	Fill the positions of senior management sales, administrative and engineering positions.

Liquidity and Capital Resources

As of May 31, 2023, PreAxia’s cash balance was $6 compared to $259 as of May 31, 2022. Our Company will be required to raise capital to fund our operations. PreAxia had a working capital deficit of $2,296,730 as of May 31, 2023 compared with a working capital deficit of $2,140,464 as of May 31, 2022.

Our ability to meet our financial liabilities and commitments is primarily dependent upon the continued issuance of equity to new stockholders and our ability to achieve and maintain profitable operations. PreAxia's cash and cash equivalents will not be sufficient to meet its working capital requirements for the next twelve-month period. We will not initially have any cash flow from operating activities as we are in the startup stage. We project that we will require an estimated $1,000,000 over the next twelve-month period pay our arms-length creditors approximately $300,000 plus an additional $700,000 to complete our business plan. The Company plans to raise the capital required to satisfy our immediate short-term needs and additional capital required to meet our estimated funding requirements for the next twelve months primarily through the private placement of our equity securities or by way of loans or such other means as PreAxia may determine.

There are no assurances that we will be able to obtain the funds required for our continued operations. There can be no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, we will not be able to meet our other obligations as they become due and we will be forced to scale down or perhaps even cease the operation of our business.

There is substantial doubt about our ability to continue as a going concern as the continuation of our business is dependent upon obtaining further long-term financing, successful and sufficient market acceptance of our products and achieving a profitable level of operations. The Company hopes to be able to attract suitable investors for our business plan, which will not require us to use our cash. There can be no assurance that the Company will be successful in this situation. The issuance of additional equity securities by us could result in a significant dilution in the equity interests of our current stockholders. Obtaining commercial loans, assuming those loans would be available, will increase our liabilities and future cash commitments.

Our working capital (deficit) as of May 31, 2023 and 2022 is summarized as follows:

Working Capital

	May 31, 2023			May 31, 2022

Current Assets	$	6		$	259
Current Liabilities		(2,296,736	)		(2,140,723	)
Working Capital (Deficit)	$	(2,296,730	)	$	(2,140,464	)

The increase in our working capital deficit of $156,266 was primarily due to increases in accrued liabilities – related party of $120,000 and Advances – related party of $32,372.

Off-balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

Results of Operations – Years ended May 31, 2023 and 2022

The following summary of our results of operations should be read in conjunction with our consolidated financial statements for the years ended May 31, 2023.

For the years ended May 31, 2023 and 2022

Our operating results for the years ended May 31, 2023 compared to the years ended May 31, 2022 are described below:

Revenue

During the years ended May 31, 2023 and 2022, the Company had revenue of $0 and $368, respectively. The Company earns a 10% commission on amounts reimbursed for eligible expenses.

Expenses

Our total expenses for the years ended May 31, 2023 was $156,266 compared to $181,011 for the years ended May 31, 2022. The decrease in total expenses of $24,745 for the years ending May 31, 2023 is due to a decrease in consulting fees of $343, decrease in professional fees of $2,072, a decrease of $3,216 in office and administration fees, and a decrease in research and development of $19,114.

Consulting Fees

During each of the years ended May 31, 2023 and 2022, Tom Zapatinas, the Chief Executive Officer and Director of the Company, earned $120,000 for consulting services provided to the Company, which is included in accounts payable and accrued liabilities – related party.

Research and Development

Research and development expenses during the years ended May 31, 2023 decreased by $19,114 to $6,528, as compared to $25,642 during the years ended May 31, 2022.

Wages and Benefits

There were no wages and benefits during the years ended May 31, 2023 and 2022.

Office and Administration

Office and administration expenses decreased by $3,216 for the years ended May 31, 2023 due to a decrease in office supply expense and filing fees.

Professional Fees

Professional fees during the years ended May 31, 2023 decreased by $2,072 to $15,504, as compared to $17,756 during the years ended May 31, 2022.

Interest Expense

Interest expense is $0 for the years ended May 31, 2023 and 2022 because accounts payable and accrued liabilities – related party, convertible note payable – related party and loans payable – shareholders are non-interest bearing.

Critical Accounting Policies

We have identified certain accounting policies, described below, that are the most important to the portrayal of our current financial condition and results of operations. Please refer to Note 2 of the accompanying consolidated financial statements for a full and complete disclosure of our accounting policies.

Revenue Recognition

In accordance with ASC 606, “Revenue from Contracts with Customers,” revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.

Gross Versus Net Revenue

ASC 606 provides guidance on proper recognition of principal versus agent considerations which is used to determine gross versus net revenue recognition. Under ASC 606, the core objective of the guidance on gross versus net revenue recognition is to help determine whether an entity is a principal or an agent in a transaction. In general, the primary difference between these two is the performance obligation being satisfied. The principal has a performance obligation to provide the desired goods or services to the end customer, whereas the agent arranges for the principal to provide the desired goods or services. Additionally, a fundamental characteristic of a principal in a transaction is control. A principal substantively controls the goods and services before they are transferred to the customer as well as controlling the price of the good or service being provided. An agent normally receives a commission or fee for these activities. In addition to control, the level at which an entity controls the price of the good or service being transferred determines principal versus agent status. The more discretion over setting price a company has in providing the good or service, the more likely they are considered a principal rather than an agent. Under the guidance when another party is involved in providing a good or service to a customer, an entity is a principal if the entity obtains control of the asset or right to a service performed by the other party.

The Company provides administrative services for Health Spending Accounts sponsored by employers (the “customer”). The Company does not take possession of goods or control the services provided as the employees of the customer are free to determine their health care provider. As such, the Company records revenue net of reimbursements to employees. The Company’s services to the customer consist of reviewing medical costs for eligibility and reimbursing employees for eligible costs.

Software Development Costs

The Company accounts for software development costs in accordance with several accounting pronouncements, including FASB ASC 730, “Research and Development,” FASB ASC 350-40, “Internal-Use Software,” FASB 985-20, “Costs of Computer Software to be Sold, Leased, or Marketed” and FASB ASC 350-50, “Website Development Costs.”

Costs incurred during the period of planning and design, prior to the period determining technological feasibility, for all software developed for use internal and external, has been charged to operations in the period incurred as research and development costs. Additionally, costs incurred after determination of readiness for market have been expensed as research and development.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA


	Page
Report of Independent Public Accounting Firm (ID 6580)	F-1

Report of Former Independent Public Accounting Firm	F-3

Audited Consolidated Financial Statements

Consolidated Balance Sheets	F-5

Consolidated Statements of Operations and Comprehensive Loss	F-6

Consolidated Statements of Changes in Stockholders’ Deficit	F-7

Consolidated Statements of Cash Flows	F-8

Notes to Consolidated Financial Statements	F-9 to F-13

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders

Preaxia Healthcare Payment Systems Inc.

Calgary, Alberta CA

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Preaxia Healthcare Payment Systems Inc. (the Company) as of May 31, 2023, and the related consolidated statements of operations and comprehensive loss, stockholders’ deficit, and cash flows for the year then ended, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of May 31, 2023, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

Going Concern Considerations

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has suffered recurring losses since inception, has a working capital deficit, and has not achieved profitable operations, which raises substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Going Concern – Disclosure

The financial statements of the Company are prepared on a going concern basis, which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations. As noted in “Going Concern Considerations” above, the Company has a history of recurring net losses, a significant accumulated deficit and currently has net working capital deficit. The Company has contractual obligations such as commitments for repayments of accounts and notes payable and accrued interest (collectively “obligations”). Currently management’s forecasts and related assumptions illustrate their ability to meet the obligations through management of expenditures, obtaining additional debt financing, loans from related and unrelated parties, and private placements of capital stock for additional funding to meet its operating needs. Should there be constraints on the ability to access financing through stock issuances, the Company will continue to manage cash outflows and meet the obligations through related and unrelated party loans.

F-1

We identified management’s assessment of the Company’s ability to continue as a going concern as a critical audit matter. Management made judgments to assess its ability to effectively implement its plans and provide the necessary cash flows to fund the Company’s obligations as they become due. Specifically, we considered the judgments with the highest degree of impact and subjectivity in determining the Company’s ability to implement its plans, including its ability to manage expenditures, its ability to access funding from capital markets, and its ability to obtain loans from related and unrelated parties. Auditing the judgments made by management required a high degree of auditor judgment and an increased extent of audit effort.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. These procedures included the following, among others, evaluating the Company’s ability to: (i) access funding from capital markets; (ii) to manage expenditures, and (iii) obtain loans from related and unrelated parties.

Other Matter

The 2022 consolidated financial statements of the Company were audited by other auditors, whose report dated September 29, 2022, included an explanatory paragraph related to the Company’s ability to continue as a going concern.

GreenGrowthCPAs

We have served as the Company’s auditor since 2023.

Los Angeles, California

August 30, 2023

F-2

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders

Preaxia Healthcare Payment Systems Inc.

Calgary, Alberta CA

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of Preaxia Healthcare Payment Systems Inc. (the Company) as of May 31, 2022, and the related consolidated statements of operations and comprehensive loss, stockholders’ deficit, and cash flows for the year then ended, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of May 31, 2022 and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

Going Concern Considerations

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has suffered recurring losses since inception, has a working capital deficit, and has not achieved profitable operations, which raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

Critical Audit Matter

F-3

Going Concern – Disclosure

/s/ Pinnacle Accountancy Group of Utah

Pinnacle Accountancy Group of Utah a dba of Heaton & Company, PLLC

We have served as the Company’s auditor since 2018.

Pinnacle Accountancy Group of Utah

Farmington, Utah

September 29, 2022

F-4

PREAXIA HEALTHCARE PAYMENT SYSTEMS INC.
CONSOLIDATED BALANCE SHEETS


	May 31, 2023			May 31, 2022

ASSETS

Current assets

Cash	$	6		$	259
Total Current Assets		6			259

Total assets	$	6		$	259

LIABILITIES

Current liabilities

Accounts payable and accrued liabilities	$	158,348		$	159,699
Accounts payable and accrued liabilities - related party		240,000			120,000
Advances - related party		64,952			32,580
Loans payable - shareholders		173,067			168,075
Liability for unissued shares		134,792			134,792
Promissory note - related party		466,817			466,817
Convertible note payable - related party		1,058,760			1,058,760
Total Current Liabilities		2,296,736			2,140,723

Total liabilities		2,296,736			2,140,723

Commitments and Contingencies		—			—

STOCKHOLDERS’ DEFICIT

Common Stock, $0.001 par value, 75,000,000 shares authorized. 19,767,698 shares issued and outstanding		19,768			19,768
Additional paid-in capital		2,655,236			2,655,236
Accumulated other comprehensive income		57,197			57,197
Accumulated deficit		(5,028,931	)		(4,872,665	)

Total Stockholders’ Deficit		(2,296,730	)		(2,140,464	)

Total liabilities and stockholders' deficit	$	6		$	259

See Accompanying Notes to the Consolidated Financial Statements

F-5

PREAXIA HEALTHCARE PAYMENT SYSTEMS INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS


	For the Years Ended
	May 31,
	2023			2022

Revenue	$	—		$	368

Cost of Sales		—			—

Gross Profit		—			368

Operating Expenses
Consulting		120,442			120,785
Professional		15,504			17,576
Office and administration		13,792			17,008
Research and development		6,528			25,642
Total Operating Expenses		156,266			181,011

Loss from Operations		(156,266	)		(180,643	)

Net loss and comprehensive loss	$	(156,266	)		(180,643	)

Net loss per share - basic and diluted	$	(0.01	)	$	(0.01	)

Weighted average number of common shares outstanding - basic and diluted		19,767,698			19,767,698

See Accompanying Notes to the Consolidated Financial Statements

F-6

PREAXIA HEALTHCARE PAYMENT SYSTEMS INC.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT


	Common Stock				Additional Paid-in		Accumulated Other Comprehensive		Accumulated			Total Stockholders'
	Shares		Amount		Capital		Income		Deficit			Deficit
Balance, May 31, 2021		19,767,698	$	19,768	$	2,655,236	$	57,197	$	(4,692,022	)	$	(1,959,821	)

Net loss and comprehensive loss		—		—		—		—		(180,643	)		(180,643	)

Balance, May 31, 2022		19,767,698	$	19,768	$	2,655,236	$	57,197	$	(4,872,665	)	$	(2,140,464	)

Net loss and comprehensive loss		—		—		—		—		(156,266	)		(156,266	)

Balance, May 31, 2023		19,767,698	$	19,768	$	2,655,236	$	57,197	$	(5,028,931	)	$	(2,296,730	)

See Accompanying Notes to the Consolidated Financial Statements

F-7

PREAXIA HEALTHCARE PAYMENT SYSTEMS INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS


	For the Years Ended May 31,
	2023			2022
Cash flows from operating activities
Net loss	$	(156,266	)	$	(180,643	)
Change in operating assets and liabilities
Increase in accounts payable and accrued liabilities - related party		120,000			120,000
Increase in accounts payable and accrued liabilities		(1,351	)		(3,328	)
Cash flows used in operating activities		(37,617	)		(63,971	)


Cash flows from investing activities		—			—

Cash flows from financing activities
Advances - related party		33,157			44,278
Repayment of advances - related party		(785	)		(11,698	)
Proceeds from the issuance of liability for unissued shares		—			—
Proceeds from loans payable - shareholders		4,992			31,610
Net cash provided by financing activities		37,364			64,190

Net change in cash		(253	)		219

Cash, beginning of the period		259			40

Cash, end of the period	$	6		$	259

Supplemental Disclosure:
Cash paid for income taxes	$	—		$	—
Cash paid for interest	$	—		$	—

Non-cash Investing and Financing Activities:
Conversion of Accounts payable and accrued liabilities - related party to Promissory note - related party	$	—		$	429,121
Conversion of Advances - related party to Promissory note - related party	$	—		$	37,696

See Accompanying Notes to the Consolidated Financial Statements

F-8

PREAXIA HEALTH CARE PAYMENT SYSTEMS INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
May 31, 2023 and 2022

Note 1 – Organization and Description of Business

PreAxia Health Care Payment Systems Inc. (the “Company” or “PreAxia”) was incorporated on April 3, 2000 in the State of Nevada. On May 31, 2005, the Company acquired all of the outstanding stock of Tiempo de Mexico Ltd. (“Tiempo”) in exchange for 5,000,000 shares of the common stock of the Company with a par value of $0.001. The Company had no operations prior to the date of the aforementioned acquisition.

The business objective of the Company is the development, distribution, marketing and sale of health care payment processing services and products. The Company has realized only nominal revenues from its planned operations.

The operations of the Company are expected to be primarily undertaken by its wholly-owned subsidiary, PreAxia Health Care Payment Ltd. (“PreAxia Payment”), incorporated pursuant to the laws of the Province of Alberta on November 26, 2015.

PreAxia Payment is in the process of developing an online access system creating a health spending account that will facilitate card payment and processing services to third-party administrators, insurance companies and others.

Note 2 – Summary of Significant Accounting Policies

This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s consolidated financial statements. The consolidated financial statements and notes are representations of the Company’s management who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the consolidated financial statements, which are stated in U.S. Dollars.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries (i) PreAxia Health Care Payment Systems Inc., incorporated pursuant to the laws of the Province of Alberta on January 28, 2008 (ii) PreAxia Canada Inc., incorporated pursuant to the laws of the Province of Alberta on January 28, 2008 and (iii) PreAxia Health Care Payment Ltd., incorporated pursuant to the laws of the Province of Alberta on November 26, 2015 (collectively, the “Subsidiaries”). All inter-company accounts and transactions have been eliminated in consolidation.

Going Concern

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. During the year ended May 31, 2023, the Company incurred a net loss of $156,266 and used cash in operating activities of $37,617, and on May 31, 2023, had a stockholders’ deficit of $2,296,730. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the consolidated financial statements are issued. The Company’s consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty should we be unable to continue as a going concern.

The Company’s ability to continue as a going concern is dependent upon its ability to develop additional sources of capital and to ultimately achieve profitable operations. Currently, the Company does not have significant cash or other material assets, nor does it have operations or a source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The Company’s officers or principal shareholders are committed to making advances or loans to pay for certain legal, accounting, and administrative costs.

The Company hopes to be able to attract suitable investors for our business plan, which will not require us to use our cash. There can be no assurance that the Company will be successful in this situation. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing.

Cash and Cash Equivalents

The Company considers all highly liquid debt instruments with an original maturity of three months or less to be cash equivalents.

Use of Estimates

The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in these consolidated financial statements and accompanying notes. Although these estimates are based on management’s knowledge of current events and actions that our company may undertake in the future, actual results could differ from those estimates.

F-9

Foreign Currency Translation

The functional currency of the Company is the United States dollar. The functional currency of the Subsidiaries is the Canadian dollar. Assets and liabilities in the accompanying consolidated financial statements are translated into United States dollars at the exchange rate in effect at the balance sheet date and capital accounts are translated at historical rates. Income statement accounts are translated at the average rates of exchange prevailing during the period. Translation adjustments arising from the use of differing exchange rates from period to period are included in the accumulated other comprehensive income (loss) account in stockholders’ deficit.

Transactions undertaken in currencies other than the functional currency of the entity are translated using the exchange rate in effect as of the transaction date. Any transaction exchange gains and losses are included in the statement of operations and comprehensive loss.

The Company's reporting currency is the U.S. dollar. All transactions initiated in Canadian Dollars are translated into U.S. dollars in accordance with Accounting Standards Codification ("ASC") 830-30, "Translation of Financial Statements," as follows:

assets and liabilities are translated at the closing rate at the date of the balance sheet of 1.00 US Dollar =1.3605 Canadian Dollars (May 31, 2023), 1.00 USD Dollar=0.593 GBP, and 1.00 US Dollar=1.2632 Canadian Dollars (May 31, 2022), 1.00 USD Dollar=0.7925 GBP;

ii)

income and expenses are translated at average exchange rates for the year ended May 31, 2023 of 1.00 US Dollar = 1.3351 Canadian Dollars and 1.00 US Dollar = 1.2632 Canadian Dollars (May 31, 2022);

iii)

all resulting exchange differences are recognized as other comprehensive income, a separate component of equity. The exchange differences during the year ended May 31, 2023 and 2022 were insignificant and no amounts have been recorded.

Fair Value of Financial Instruments

The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Management uses a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

☐

Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

☐

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

☐

Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

The fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of May 31, 2023 and, 2022. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

Net Loss Per Share

Net loss per share of common stock is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. The Company has 10,587,600 shares of potential common stock equivalents for convertible note payable – related party outstanding during the periods ended May 31, 2023 and 2022, which have been excluded from the loss per share computation as their effect would have been anti-dilutive due to net losses.

Research and Development Costs

The Company expenses research and development costs as incurred in accordance with FASB ASC 730 “Research and Development.” During the years ended May 31, 2023 and 2022, we incurred $6,528 and $25,642, respectively, in research and development expenses.

Software Development Costs

F-10

The Company will capitalize certain costs in the development of our proprietary software (computer software to be sold, leased or licensed) for the period after technological feasibility was determined and prior to our marketing and initial sales.

Website development costs are capitalized under the same criteria as our marketed software.

Impairment of Long-lived Assets

Long-lived assets such as property, equipment and identifiable intangibles are reviewed for impairment whenever facts and circumstances indicate that the carrying value may not be recoverable. When required, impairment losses on assets to be held and used are recognized based on the fair value of the asset. The fair value is determined based on estimates of future cash flows, market value of similar assets, if available, or independent appraisals, if required. If the carrying amount of the long-lived asset is not recoverable from its undiscounted cash flows, an impairment loss is recognized for the difference between the carrying amount and fair value of the asset. When fair values are not available, the Company estimates fair value using the expected future cash flows discounted at a rate commensurate with the risk associated with the recovery of the assets. We did not recognize any impairment losses for any periods presented.

Commitments and Contingencies

The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.

Revenue Recognition

Gross Versus Net Revenue

During the years ended May 31, 2023 and 2022, the Company had revenue of $0 and $368, respectively. The Company earns a 10% commission on amounts reimbursed for eligible expenses.

Income Taxes

The Company follows Section 740-10-30 of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the fiscal year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Income and Comprehensive Income in the period that includes the enactment date.

F-11

The Company follows section 740-10-25 of the FASB Accounting Standards Codification (“Section 740-10-25”) with regards to uncertain income tax positions. Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures.

Note 3 – Recent Accounting Pronouncements

The Company reviews new accounting standards as issued or updated. No new standards or updates had any material effect on these consolidated financial statements. The accounting pronouncements issued subsequent to the date of these consolidated financial statements that were considered significant by management were evaluated for the potential effect on these consolidated financial statements. Management does not believe any of the subsequent pronouncements will have a material effect on these consolidated financial statements as presented.

Note 4 – Related Party Transactions

As of May 31, 2023 and 2022, accounts payable and accrued liabilities – related party due to Tom Zapatinas totaled $240,000 and $120,000, respectively. During the years ended May 31, 2023 and 2022, Tom Zapatinas, the Chief Executive Officer and Director of the Company, earned $120,000 and $120,000, respectively, for consulting services provided to the Company. On May 31, 2022, accounts payable and accrued liabilities – related party of $429,121 was settled by issuing promissory note – related party below.

Advances – Related Party

As of May 31, 2023 and 2022, advances payable due to Tom Zapatinas totaled $64,952 and $32,580, respectively. During the year ended May 31, 2023 and 2022, Tom Zapatinas, the Chief Executive Officer and a Director of the Company, advanced the Company $33,157 and $44,278, respectively, in cash and was repaid $785 and $11,698, respectively, in cash. On May 31, 2022, advances – related party of $37,696 was settled by issuing promissory note – related party below.

Loans Payable – Shareholders

As of May 31, 2023 and 2022, loans payable - shareholders are $173,067 and $168,075, respectively. Loans payable – shareholders are unsecured, non-interest bearing and due on demand. During the years ended May 31, 2023 and 2022, the Company was advanced $4,992 and $31,610, respectively, in cash, and was repaid $0 and $0, respectively, in cash.

Promissory Note – Related Party

As of May 31, 2023 and 2022, promissory note - related party of $466,817 and $466,817, respectively, is due to Tom Zapatinas, the Chief Executive Officer and a Director of the Company. The Note is non-interest bearing, unsecured and payable on demand. The note payable – related party was issued on May 31, 2022, to settle accounts payable and accrued liabilities – related party of $429,121 and advance – related party of $37,696.

Convertible Note Payable – Related Party

As of May 31, 2023 and 2022, convertible note payable - related party of $1,058,760 is due to Tom Zapatinas, the Chief Executive Officer and a Director of the Company. The Note is non-interest bearing, unsecured, payable on demand and convertible in whole or in part into shares of common stock of the Company at a conversion price of $0.10 per share, which equates to 10,587,600 shares.

F-12

Note 5 – Income Taxes

As of May 31, 2023, the Company is in arrears on filing its statutory income tax returns. Tax years 2008 through 2023 are open for examination by taxing authorities. The Company has incurred substantial net operating losses of approximately $4,189,000 since January 28, 2008 (Date of Inception).


	2023			2022

Net operating losses – U.S. parent:
Amount carried forward from prior years	$	(872,137	)	$	(859,324	)
Net operating losses (21% tax rate)		(32,815	)		(38,013	)
Accrued management compensation		25,200			25,200
Total		(879,752	)		(872,137	)
The Company’s deferred tax assets and liabilities consist primarily of the following:

Deferred taxes – U.S. Parent		(879,752	)		(872,137	)
Net operating losses – Canadian subsidiary:
Amount carried forward from prior years		(31,760	)		(31,760	)
Net operating losses		—			—
Deferred taxes – Canadian subsidiary		(31,760	)		(31,760	)

Total deferred tax assets		(911,512	)		(903,897	)
Less: valuation allowance		911,512			903,897
Total net deferred tax assets	$	—		$	—

During the years ended May 31, 2023 and 2022, the change in valuation allowance was an increase of $7,615 in 2023 and an increase of $12,813 in 2022.

The Company has no tax positions at May 31, 2023 and 2022 for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. No such interest or penalties were recognized during the period presented. The Company had no accruals for interest and penalties at May 31, 2023 and 2022.

Note 6 – Stockholders’ Deficit

Common Stock

Common Stock, par value of $0.001 per share; 75,000,000 shares authorized: 19,767,698 shares issued and outstanding at May 31, 2023 and 2022. Holders of Common Stock have one vote per share of Common Stock held.

Note 7 – Contingencies and Commitments

From time to time the Company may be a party to litigation matters involving claims against the Company. Management believes that there are no current matters that would have a material effect on the Company’s financial position or results of operations.

The Company does not have long-term commitments for equipment purchases or leases. The Company presently operates from remote employment sites.

Note 8 – Subsequent Events

The Company has evaluated all subsequent events through the date these financial statements were issued and no subsequent events occurred that required disclosure.

F-13

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Management, evaluated the effectiveness of our disclosure controls and procedures, as defined under Exchange Act Rule 13a-15(e). Based upon this evaluation, the Chief Executive Officer concluded that, as of May 31, 2023, the disclosure controls and procedures were not effective. The ineffectiveness of our Company’s disclosure controls and procedures was due to the existence of material weaknesses identified below.

Disclosure controls and procedures are the controls and other procedures that are designed to ensure that information required to be disclosed in our Company’s Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities Exchange Commission’s rules and forms.

Management’s Report On Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined under Exchange Act Rules 13a-15(f) and 14d-14(f). Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

All internal control systems, no matter how well designed, have inherent limitations and may not prevent or detect misstatements. Therefore, even those systems determined to be effective can only provide reasonable assurance with respect to financial reporting reliability and financial statement preparation and presentation. In addition, projections of any evaluation of effectiveness to future periods are subject to risk that controls become inadequate because of changes in conditions and that the degree of compliance with the policies or procedures may deteriorate.

Management assessed the effectiveness of our company’s internal control over financial reporting as of May 31, 2023. In making the assessment, management used the criteria issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO - 2013) in Internal Control-Integrated Framework. Based on its assessment, management concluded that, as of May 31, 2023, our Company’s internal control over financial reporting was not effective.

Management has identified the following material weaknesses:

We do not have accounting staff with sufficient technical accounting knowledge relating to accounting for U.S. income taxes and complex US GAAP matters; and

We failed to file our corporate tax returns for 2008 through 2023.

We intend to take appropriate and reasonable steps to make the necessary improvements to remediate these material weaknesses. In particular, we intend to hire staff with U.S. GAAP expertise if we can obtain additional financing and hire professionals to prepare and complete the filing of our corporate tax returns.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal controls over financial reporting that occurred during our fourth fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

ITEM 9B. OTHER INFORMATION

None.

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Directors and Executive Officers

The following individual serves as the director and executive officers of our Company. All directors of our Company hold office until the next annual meeting of our shareholders or until their successors have been elected and qualified. The executive officers of our Company are appointed by our board of directors and hold office until their death, resignation or removal from office.

Name	Position	Age	Date First Elected or Appointed
Tom Zapatinas	President, Chief Executive Officer, Secretary, Chief Financial Officer, Treasurer and Director	65	Director since January 9, 2007 Officer since January 25, 2008
Paul Verberne	Director	58	Director since June 1, 2018

Significant Employees

There are no family relationships between or among our directors or executive officers.

Business Experience

Tom Zapatinas, President, Secretary, Chief Executive Officer, Chief Financial Officer and a director

Tom Zapatinas has been a director of our Company since January 9, 2007 and the president, secretary, chief executive officer and chief financial officer of our company since January 25, 2008. Mr. Zapatinas has been a self-employed business consultant since August 1997. In June of 1998, Mr. Zapatinas founded Prolific Smart Card Software Systems Inc. which became a reporting issuer on the TSX Venture Exchange in Canada. Mr. Zapatinas resigned from Prolific in May 29, 2001, to go back to his consulting practice. He brings experience in financing, corporate development and mergers and acquisitions.

Mr. Zapatinas is not an officer or director of any other reporting company that files annual, quarterly or periodic reports with the United States Securities and Exchange Commission.

We believe Mr. Zapatinas is qualified to serve on our board of directors because of his knowledge of our company’s history and current operations, which he gained from working for our company as described above, in addition to his business experiences as described above.

Paul Verberne, member of the Board of Directors

Mr. Verberne has been involved in the Healthcare Spending Account (HSA) industry since 2004, when he became counsel for HSA Bank (a division of Webster Bank). He provided legal and business expertise focused on tax favoured benefit accounts, helping HSA Bank grow from $8 million in HSA deposits to over $800 million in six years. HSA Bank is now a leading HSA provider in the USA with over $5 billion in assets. Mr. Verberne was also general counsel to the American Banker's Association HSA Council and Tango Health, a leading benefits optimization solutions provider. He is currently a principal in HSA Consulting Services, LLC, which provides training and expertise to the HSA industry, and a partner in Verberne & Maldonado LLP in Houston, a law firm concentrating in business law. He received his B.A. in Liberal Arts (Economics/Psychology) from the University of Texas (Austin) and a Juris Doctorate from University of Houston Law Center. Mr. Verberne will be providing strategic advice and guidance to PreAxia as it develops, rolls out and expands its HSA Management Solution throughout Canada and the USA.

Involvement in Certain Legal Proceedings

Our directors or executive officers have not been involved in any of the following events during the past ten years:

	1.	any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;

	2.	any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offences);

	3.	being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities; or

	4.	being found by a court of competent jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated.

	5.	being the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of: (i) any federal or state securities or commodities law or regulation; or (ii) any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease- and-desist order, or removal or prohibition order; or (iii) any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or

	6.	being the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a) (26) of the Securities Exchange Act of 1934), any registered entity (as defined in Section 1(a) (29) of the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

Audit Committee

The Corporation is a “venture issuer” as defined in National Instrument 52-110 and is relying on the exemption contained in Section 6.1 of National Instrument 52-110, which exempts the Corporation from the requirements of Part 3 (Composition of the Audit Committee) and Part 5 (Reporting Obligations) of National Instrument 52-110.

The Audit Committee’s Charter

Mandate

The primary function of the audit committee (the "Committee") is to assist the Board of Directors in fulfilling its financial oversight responsibilities by reviewing the financial reports and other financial information provided by the Corporation to regulatory authorities and shareholders, the Corporation’s systems of internal controls regarding finance and accounting and the Corporation’s auditing, accounting and financial reporting processes. Consistent with this function, the Committee will encourage continuous improvement of, and should foster adherence to, the Corporation’s policies, procedures and practices at all levels. The Committee’s primary duties and responsibilities are to:

Serve as an independent and objective party to monitor the Corporation’s financial reporting and internal control system and review the Corporation’s financial statements.

Review and appraise the performance of the Corporation’s external auditors.

Provide an open avenue of communication among the Corporation’s auditors, financial and senior management and the Board of Directors.

Composition

The Committee shall be comprised of two directors as determined by the Board of Directors, whom shall be free from any relationship that, in the opinion of the Board of Directors, would interfere with the exercise of his or her independent judgment as a member of the Committee.

The members of the Committee shall be elected by the Board of Directors at its first meeting following the annual shareholders’ meeting. Unless a Chair is elected by the full Board of Directors, the members of the Committee may designate a Chair by a majority vote of the full Committee membership.

Meetings

The Committee shall meet annually, or more frequently as circumstances dictate. As part of its job to foster open communication, the Committee will meet at least annually with the Chief Financial Officer and the external auditors.

Responsibilities and Duties

To fulfill its responsibilities and duties, the Committee shall:

Documents/Reports Review

	(a)	Review and update this Charter annually.

	(b)	Review the Corporation’s financial statements, MD&A and any reports or other financial information (including quarterly financial statements), which are submitted to any governmental body, or to the public, including any certification, report, opinion, or review rendered by the external auditors.

External Auditors

(a)

Review annually, the performance of the external auditors who shall be ultimately accountable to the Board of Directors and the Committee as representatives of the shareholders of the Corporation.

(b)

Obtain annually, a formal written statement of the external auditors setting forth all relationships between the external auditors and the Corporation, consistent with PCAOB Rule 3526.

(c)

Review and discuss with the external auditors any disclosed relationships or services that may impact the objectivity and independence of the external auditors.

(d)

Take, or recommend that the full Board of Directors take, appropriate action to oversee the independence of the external auditors.

(e)

Recommend to the Board of Directors the selection and, where applicable, the replacement of the external auditors nominated annually for shareholder approval.

(f)

At each meeting, consult with the external auditors, without the presence of management, about the quality of the Corporation’s accounting principles, internal controls and the completeness and accuracy of the Corporation’s financial statements.

(g)

Review with management and the external auditors the audit plan for the year-end financial statements and intended template for such statements.

(h)

Review and pre-approve all audit and audit related services and the fees and other compensation related thereto, and any non-audit services, provided by the Corporation’s external auditors. The pre-approval requirement is waived with respect to the provision of non-audit services if:

	(i)	the aggregate amount of all such non-audit services provided to the Corporation constitutes not more than five percent of the total amount of revenues paid by the Corporation to its external auditors during the fiscal year in which the non-audit services are provided;
	(ii)	such services were not recognized by the Corporation at the time of the engagement to be non-audit services; and
	(iii)	such services are promptly brought to the attention of the Committee by the Corporation and approved prior to the completion of the audit by the Committee or by one or more members of the Committee who are members of the Board of Directors to whom authority to grant such approvals have been delegated by the Committee.

Provided the pre-approval of the non-audit services is presented to the Committee's first scheduled meeting following such approval such authority may be delegated by the Committee to one or more independent members of the Committee.

Financial Reporting Processes

(a)		In consultation with the external auditors, review with management the integrity of the Corporation’s financial reporting process, both internal and external.

(b)		Consider the external auditors’ judgments about the quality and appropriateness of the Corporation’s accounting principles as applied in its financial reporting.

(c)		Consider and approve, if appropriate, changes to the Corporation’s auditing and accounting principles and practices as suggested by the external auditors and management.

(d)		Review significant judgments made by management in the preparation of financial statements and the view of the external auditors as to the appropriateness of such judgments.

(e)		Following completion of the annual audit, review separately with management and the external auditors any significant difficulties encountered during the course of the audit, including any restrictions on the scope of work or access to required information.
(f)	Review any significant disagreement among management and the external auditors in connection with the preparation of the financial statements.

(g)	Review with the external auditors and management the extent to which changes and improvements in financial or accounting practices have been implemented.

(h)	Review any complaints or concerns about questionable accounting, internal accounting controls or auditing matters.

(i)	Review certification process.

Other

Review any related-party transactions.

Members of the Audit Committee

Member

Independence

Financially Literate

Tom Zapatinas

Paul Verberne

Not Independent

Not Financially literate

CORPORATE GOVERNANCE

Corporate Governance relates to the activities of the Board of Directors. National Policy 58-201 establishes corporate governance guidelines which apply to all public companies. The Corporation has reviewed its own corporate governance practices in light of these guidelines. In certain cases, the Corporation’s practices comply with the guidelines, however, the Board considers that some of the guidelines are not suitable for the Corporation at its current stage of development and therefore these guidelines have not been adopted. National Policy 58-201 mandates disclosure of corporate governance practices which disclosure is set out below. The Board is committed to sound corporate governance practices in the interest of its shareholders and contribute to effective and efficient decision making. The Corporation will continue to review and implement corporate governance guidelines as the business of the Corporation progresses.

Independence of Members of Board

The Corporation’s Board consists of two directors, Paul Verberne and Tom Zapatinas. Of which Tom Zapatinas is not independent as he is the Chief Executive Officer of the Corporation.

Management Supervision by Board

The size of the Corporation is such that all of the Corporation’s operations are conducted by a small management team which is also represented on the Board. The Board considers that management is effectively supervised by the director on an informal basis as the director is actively and regularly involved in reviewing the operations of the Corporation and has regular and full access to management.

Other Directorships

Paul Verberne or Tom Zapatinas is not a director of any other reporting issuers.

Orientation and Continuing Education

The Board does not have a formal orientation or education program for its members. New Board members are provided with information respecting the functioning of the Board of Directors, audit committee, access to all of the publicly filed documents of the Corporation and complete access to management and the Corporation’s professional advisors.

Board members are encouraged to communicate with management and the auditors, to keep themselves current with industry trends and developments and changes in legislation with the Corporation’s assistance, to attend industry seminars and to visit the Corporation’s operations. Board members have full access to the Corporation’s records and legal counsel.

Ethical Business Conduct

The Board believes good corporate governance in an integral component to the success of the Corporation and to meet responsibilities to shareholders.

At present the Board has not adopted guidelines or stipulations or a code to encourage and promote a culture of ethical business conduct due to the size of its Board and its limited activities. The Corporation does promote ethical business conduct through the nomination of Board members it considers ethical.

Nomination of Directors

The Board has responsibility for identifying and assessing potential Board candidates. Recruitment of new directors has generally resulted from recommendations made by directors, management and shareholders. The Board assesses potential Board candidates to fill perceived needs on the Board for required skills, expertise, independence and other factors.

Compensation of Directors and the CEO

The directors decide as a Board the compensation for the Corporation’s directors and officers. Compensation payable is determined by considering compensation paid for directors and CEOs of companies of similar size and stage of development in the health care payment industry and determining appropriate compensation reflecting the need to provide incentive and compensation for the time and effort expended by the directors and senior management while taking into account the financial and other resources of the Corporation. In setting the compensation, the performance of the CEO is reviewed in light of the Corporation’s objectives and other factors that may have impacted the success of the Corporation.

Board Committees

The Corporation has an Audit Committee (see section entitled “Audit Committee”).

The Board is of the view that the size of the Corporation’s operations does not warrant additional committees at this stage of the Corporation’s development.

Assessments

The Board does not consider that formal assessments would be useful at this stage of the Corporation’s development.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act requires our executive officers and directors, and persons who own more than 10% of our common stock, to file reports regarding ownership of, and transactions in, our securities with the Securities and Exchange Commission and to provide us with copies of those filings. Based solely on our review of the copies of such forms received by us, or written representations from certain reporting persons, we believe that during the fiscal year ended May 31, 2023 all filing requirements applicable to our executive officers, directors and greater than 10% percent beneficial owners were complied with.

ITEM 11. EXECUTIVE COMPENSATION

The following table sets forth all compensation received during the two years ended May 31, 2023 and 2022 by our principal executive officer and principal financial officer and each of the other most highly compensated executive officers whose total compensation exceeded $100,000 in such fiscal year. These officers are referred to as the Named Executive Officers in this report.

Summary Compensation

The following table provides a summary of the compensation received by the persons set out therein for each of our last two fiscal years:

SUMMARY COMPENSATION TABLE

Name and
Principal
Position

Year

Salary
($)

Bonus
($)

Stock
Awards
($)

Option
Awards
($)

Non-Equity
Incentive Plan
Compensation
($)

Change in
Pension
Value and
Nonqualified
Deferred
Compensa-
tion Earnings
($)

All Other
Compensa
-tion
($)

Total
($)

Tom Zapatinas,
President, CEO and
Director

2023
2022

$120,000
$120,000

Nil
Nil

$120,000
$120,000

Employment Agreements

There are currently no employment agreements in effect.

Pension, Retirement or Similar Benefit Plans

There are no arrangements or plans in which we provide pension, retirement or similar benefits for directors or executive officers. We adopted and approved our current stock option plan on January 28, 2010, pursuant to which we may grant stock options to acquire up to 2,000,000 shares of our common stock. Our directors and executive officers may receive stock options at the discretion of our board of directors in the future. We do not have any material bonus or profit sharing plans pursuant to which cash or non-cash compensation is or may be paid to our directors or executive officers, except that stock options may be granted at the discretion of our board of directors from time to time.

Termination of Employment and Change in Control Arrangements

We have no plans or arrangements in respect of remuneration received or that may be received by our executive officers to compensate such officers in the event of termination of employment (as a result of resignation, retirement, change of control) or a change of responsibilities following a change of control.

Outstanding Equity Awards at Fiscal Year-End

The following table sets forth for each named executive officer certain information concerning the outstanding equity awards as of May 31, 2023.

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END
OPTION AWARDS						STOCK AWARDS
Name	Number of Securities Underlying Unexercised Options (#) Exercisable	Number of Securities Underlying Unexercised Options (#) Unexercisable	Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)	Option Exercise Price ($)	Option Expiration Date	Number of Shares or Units of Stock That Have Not Vested (#)	Market Value of Shares or Units of Stock That Have Not Vested ($)	Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)	Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested (#)
Tom Zapatinas	None	None	None	None	None	None	None	None	None

Aggregated Option Exercises

There were no options granted or exercised by any executive officer or director of our company during the twelve-month period ended May 31, 2023.

Directors Compensation

We reimburse our directors for expenses incurred in connection with attending board meetings but did not pay director’s fees or other cash compensation for services rendered as a director in the year ended May 31, 2023. We have no present formal plan for compensating our directors for their service in their capacity as directors, although in the future, such directors are expected to receive compensation and options to purchase shares of common stock as awarded by our board of directors or (as to future options) a compensation committee which may be established in the future. Directors are entitled to reimbursement for reasonable travel and other out-of-pocket expenses incurred in connection with attendance at meetings of our board of directors. The board of directors may award special remuneration to any director undertaking any special services on behalf of our company other than services ordinarily required of a director. Other than indicated in this annual report, no director received and/or accrued any compensation for his or her services as a director, including committee participation and/or special assignments.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Security ownership of certain beneficial owners

The following table sets forth, as of August 30, 2023, certain information with respect to the beneficial ownership of our common stock by our current directors and executive officers as a group. Each person has sole voting and investment power with respect to the shares of common stock they hold, except as otherwise indicated. Beneficial ownership consists of a direct interest in the shares of common stock, except as otherwise indicated. As of August 30, 2023, there were no shareholders known by us to be the beneficial owner of more than 5% of our common stock except as set forth in the following table.

Security ownership of management

Title of Class	Name and Address of Beneficial Owner	Amount and Nature of Beneficial Ownership ⁽¹⁾		Percentage of Class ⁽²⁾
Common Stock	Tom Zapatinas	9,100,000	Direct	46.03%
	3212 – 14 Avenue SW
	Calgary, AB T3C 0X3
Common Stock	Paul Verberne 3212 – 14 Avenue SW Calgary, AB T3C 0X3	-		-
Common Stock	All officers and directors as a group (2 persons)	9,100,000		46.03%

(1) Except as otherwise indicated, we believe that the beneficial owners of the common stock listed above, based on information furnished by such owners, have sole investment and voting power with respect to such shares, subject to community property laws where applicable. Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities. Shares of common stock subject to options or warrants currently exercisable, or exercisable within 60 days, are deemed outstanding for purposes of computing the percentage ownership of the person holding such option or warrants, but are not deemed outstanding for purposes of computing the percentage ownership of any other person.

(2) Based upon 19,767,698 issued and outstanding shares of common stock as of August 30, 2023.

Changes in Control

We are unaware of any contract or other arrangement the operation of which may at a subsequent date result in a change of control of our company.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

Other than as listed below, no director, officer, principal shareholder holding at least 5% of our common shares, or any family member thereof, had any material interest, direct or indirect, in any transaction, or proposed transaction, since the beginning of our fiscal year ended May 31, 2023, in which the amount involved in the transaction exceeded or exceeds the lesser of $120,000 or one percent of the average of our total assets at year-end for the last two completed fiscal years.

During the year ended May 31, 2023, the Company’s president, Tom Zapatinas, invoiced $120,000 for management services rendered to the Company, advanced $33,157 in cash and received repayments of $785 in cash. As of May 31, 2023, Accounts payable – related party and Advances – related party includes a total of $304,952 due and payable to Mr. Zapatinas. The balance as of May 31, 2022 was $152,580.

As of May 31, 2023 and 2022, loans payable - shareholders are $173,067 and $168,075, respectively. Loans payable – shareholders are unsecured, non-interest bearing and due on demand or due within one year after the issuance date. During the years ended May 31, 2023 and 2022, the Company was advanced $0 and $31,610, respectively, in cash, and was repaid $0 and $0, respectively, in cash.

Director Independence

We do not currently have any directors that would fit the independence requirements of Rule 5605(a)(2) of the Nasdaq Marketplace Rules.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

Audit fees

The aggregate fees billed by Heaton and Company, PLLC (dba as Pinnacle Accountancy Group of Utah) for the completed fiscal periods ended May 31, 2023 and 2022 for professional services rendered for the audit of our annual financial statements, quarterly reviews of our interim financial statements and services normally provided by the independent accountant in connection with statutory and regulatory filings or engagements for these fiscal periods were as follows:

	Year Ended May 31, 2023		Year Ended May 31, 2022
Audit Fees and Audit Related Fees	$	10,000	$	10,000
Tax Fees		—		—
All Other Fees		—		—
Total	$	10,000	$	10,000

In the above tables, “audit fees” are fees billed by our company’s external auditor for services provided in auditing our company’s annual financial statements for the subject year. “Audit-related fees” are fees not included in audit fees that are billed by the auditor for assurance and related services that are reasonably related to the performance of the audit and review of our company’s financial statements. “Tax fees” are fees billed by the auditor for professional services rendered for tax compliance, tax advice and tax planning. “All other fees” are fees billed by the auditor for products and services not included in the foregoing categories.

Policy on Pre-Approval by Audit Committee of Services Performed by Independent Auditors

The board of directors pre-approves all services provided by our independent auditors. All of the above services and fees were reviewed and approved by the board of directors before the respective services were rendered.

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

Exhibit Number	Description
3.1	Articles of Incorporation (Incorporated by reference to the Exhibits filed with the Form SB-2 filed with the SEC on March 16, 2006)
3.2	Certificate of Amendment to Articles of Incorporation (Incorporated by reference to the Exhibits filed with Schedule 14C on November 14, 2008)
3.3	Bylaws (Incorporated by reference to the Exhibits filed with the Form SB-2 filed with the SEC on March 16, 2006)
3.4	Amended Bylaws (Incorporated by reference to the Exhibits filed with the Form SB-2 filed with the SEC on March 16, 2006)
10.1	Share Exchange Agreement dated May 31, 2005 between Kimberley Coonfer, Caribbean Overseas Investments Ltd., Sun World Partners Inc. and Tiempo De Mexico Ltd. (Incorporated by reference to the Exhibits filed with the Form SB-2 filed with the SEC on March 16, 2006)
10.2	Letter of Intent dated February 22, 2008 between Sun World Partners Inc. and H Pay Card Ltd. (Incorporated by reference to the Exhibits filed with the Form 8-K on March 5, 2008)
10.3	Acquisition Agreement dated April 22, 2008 (Incorporated by reference to the Exhibits filed with the Form 8-K on May 19, 2008)
10.4	Promissory note dated June 1, 2011 issued to Macleod Projects Inc. (Incorporated by reference to the Exhibits filed with the annual report on Form 10-K for the year ended May 31, 2011 filed with the SEC on October 21, 2011)
10.5	Promissory note dated August 5, 2011 issued to Macleod Projects Inc. (Incorporated by reference to the Exhibits filed with the annual report on Form 10-K for the year ended May 31, 2011 filed with the SEC on October 21, 2011 )

10.6	Promissory note dated August 31, 2017 issued to 2001033 Alberta Ltd. (Incorporated by reference to the Exhibits filed with the annual report on Form 10-K for the year ended May 31, 2018 filed with the SEC on September 13, 2018)
10.7	Promissory note dated May 31, 2018 issued to 1378655 Alberta Ltd. (Incorporated by reference to the Exhibits filed with the annual report on Form 10-K for the year ended May 31, 2018 filed with the SEC on September 13, 2018)
31.1*	Section 302 Certification of Principal Executive Officer
31.2*	Section 302 Certification of Principal Financial Officer
32.1*	Certification Pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*	Certification Pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*	XBRL INSTANCE DOCUMENT
101.SCH*	XBRL TAXONOMY EXTENSION SCHEMA
101.CAL*	XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
101.DEF*	XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
101.LAB*	XBRL TAXONOMY EXTENSION LABEL LINKBASE
101.PRE*	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

*Filed Herewith.

ITEM 16. FORM 10-K SUMMARY. None

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PREAXIA HEALTH CARE PAYMENT SYSTEMS INC.

/s/ Tom Zapatinas
By: Tom Zapatinas, President and Director
(Principal Executive Officer, Principal Financial Officer and Director)
Dated: August 30, 2023

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

/s/ Tom Zapatinas
By: Tom Zapatinas, President and Director
(Principal Executive Officer, Principal Financial Officer and Director)
Dated: August 30, 2023

/s/ Paul Verberne
By: Paul Verberne, Director
Dated: August 30, 2023

EX-31 2 ex31.htm EXHIBIT 31

EXHIBIT 31.1

RULE 13a-14(a)/15d-14(a) CERTIFICATION

I, Tom Zapatinas, certify that:

1. I have reviewed this annual report on Form 10- K for the year ended May 31, 2023 of PreAxia Health Care Payment Systems Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles,

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

August 30, 2023


	/s/ Tom Zapatinas
	Tom Zapatinas, Principal Executive Officer, Principal Financial Officer and Director

EX-32 3 ex32.htm EXHIBIT 32

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of PreAxia Health Care Payment Systems Inc. (the “Company”) on Form 10-K for the year ended May 31, 2023 as filed with the Securities and Exchange Commission (the “Report”), I, Tom Zapatinas, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. SS. 1350, as adopted pursuant to SS. 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.



August 30, 2023	/s/ Tom Zapatinas
	Tom Zapatinas, Principal Executive Officer, Chief Financial Officer and Director

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

GRAPHIC 4 image_001.jpg GRAPHIC begin 644 image_001.jpg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end GRAPHIC 5 image_002.jpg GRAPHIC begin 644 image_002.jpg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end EX-101.SCH 6 paxh-20230531.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stockholders’ Deficit link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Contingencies and Commitments link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Organization and Description of Business (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Stockholders’ Deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 paxh-20230531_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 paxh-20230531_def.xml XBRL DEFINITION FILE EX-101.LAB 9 paxh-20230531_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Plan Name [Axis] Tiempo De Mexico Ltd [Member] Class of Stock [Axis] Common Stocks [Member] Geographic Distribution [Axis] UNITED STATES Canada Dollars [Member] U S D [Member] G B P [Member] Income Statement Location [Axis] Income And Expenses [Member] Antidilutive Securities [Axis] Convertible Notes Payable Related Party [Member] Related Party Transaction [Axis] Tom Zapatinas [Member] Related Party, Type [Axis] Chief Executive Officer [Member] Long-Term Debt, Type [Axis] Promissory Note Related Party [Member] Consolidated Entities [Axis] Parent Company [Member] Subsidiaries [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Document Financial Statement Error Correction [Flag] Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] ASSETS Current assets Cash Total Current Assets Total assets LIABILITIES Current liabilities Accounts payable and accrued liabilities Accounts payable and accrued liabilities - related party Advances - related party Loans payable - shareholders Liability for unissued shares Promissory note - related party Convertible note payable - related party Total Current Liabilities Total liabilities Commitments and Contingencies STOCKHOLDERS’ DEFICIT Common Stock, $0.001 par value, 75,000,000 shares authorized. 19,767,698 shares issued and outstanding Additional paid-in capital Accumulated other comprehensive income Accumulated deficit Total Stockholders’ Deficit Total liabilities and stockholders' deficit Common stock, par value per share Common stock, shares authorized Common stock, shares outstanding Common stock, shares issued Income Statement [Abstract] Revenue Cost of Sales Gross Profit Operating Expenses Consulting Professional Office and administration Research and development Total Operating Expenses Loss from Operations Net loss and comprehensive loss Net loss per share - basic Net loss per share - diluted Weighted average number of common shares outstanding - basic Weighted average number of common shares outstanding - diluted Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares Net loss and comprehensive loss Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities Net loss Change in operating assets and liabilities Increase in accounts payable and accrued liabilities - related party Increase in accounts payable and accrued liabilities Cash flows used in operating activities Cash flows from investing activities Cash flows from financing activities Advances - related party Repayment of advances - related party Proceeds from the issuance of liability for unissued shares Proceeds from loans payable - shareholders Net cash provided by financing activities Net change in cash Cash, beginning of the period Cash, end of the period Supplemental Disclosure: Cash paid for income taxes Cash paid for interest Non-cash Investing and Financing Activities: Conversion of Accounts payable and accrued liabilities - related party to Promissory note - related party Conversion of Advances - related party to Promissory note - related party Accounting Policies [Abstract] Organization and Description of Business Summary of Significant Accounting Policies Accounting Changes and Error Corrections [Abstract] Recent Accounting Pronouncements Related Party Transactions [Abstract] Related Party Transactions Income Tax Disclosure [Abstract] Income Taxes Equity [Abstract] Stockholders’ Deficit Commitments and Contingencies Disclosure [Abstract] Contingencies and Commitments Subsequent Events [Abstract] Subsequent Events Principles of Consolidation Going Concern Cash and Cash Equivalents Use of Estimates Foreign Currency Translation Fair Value of Financial Instruments Net Loss Per Share Research and Development Costs Software Development Costs Impairment of Long-lived Assets Commitments and Contingencies Revenue Recognition Gross Versus Net Revenue Income Taxes EX-101.PRE 10 paxh-20230531_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover - USD ($)	12 Months Ended
Cover - USD ($)	May 31, 2023	Aug. 30, 2023	Nov. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	May 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--05-31
Entity File Number	000-53490
Entity Registrant Name	PREAXIA HEALTH CARE PAYMENT SYSTEMS INC.
Entity Central Index Key	0001350156
Entity Tax Identification Number	20-4395271
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	PO Box 34075 Westbrook PO
Entity Address, Address Line Two	1610-37th Street S.W.
Entity Address, City or Town	Calgary
Entity Address, State or Province	AB
Entity Address, Postal Zip Code	T3C 3W2
City Area Code	403
Local Phone Number	850-4120
Title of 12(g) Security	Common Stock, $0.001 par value
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 602,725
Entity Common Stock, Shares Outstanding		19,767,698
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	6580
Auditor Name	GreenGrowthCPAs
Auditor Location	Los Angeles, California

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($)	May 31, 2023	May 31, 2022
Current assets
Cash	$ 6	$ 259
Total Current Assets	6	259
Total assets	6	259
Current liabilities
Accounts payable and accrued liabilities	158,348	159,699
Accounts payable and accrued liabilities - related party	240,000	120,000
Advances - related party	64,952	32,580
Loans payable - shareholders	173,067	168,075
Liability for unissued shares	134,792	134,792
Promissory note - related party	466,817	466,817
Convertible note payable - related party	1,058,760	1,058,760
Total Current Liabilities	2,296,736	2,140,723
Total liabilities	2,296,736	2,140,723
Commitments and Contingencies
STOCKHOLDERS’ DEFICIT
Common Stock, $0.001 par value, 75,000,000 shares authorized. 19,767,698 shares issued and outstanding	19,768	19,768
Additional paid-in capital	2,655,236	2,655,236
Accumulated other comprehensive income	57,197	57,197
Accumulated deficit	(5,028,931)	(4,872,665)
Total Stockholders’ Deficit	(2,296,730)	(2,140,464)
Total liabilities and stockholders' deficit	$ 6	$ 259

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	May 31, 2023	May 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares outstanding	19,767,698	19,767,698
Common stock, shares issued	19,767,698	19,767,698

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	May 31, 2023	May 31, 2022
Income Statement [Abstract]
Revenue	$ 0	$ 368
Cost of Sales	0	0
Gross Profit	0	368
Operating Expenses
Consulting	120,442	120,785
Professional	15,504	17,576
Office and administration	13,792	17,008
Research and development	6,528	25,642
Total Operating Expenses	156,266	181,011
Loss from Operations	(156,266)	(180,643)
Net loss and comprehensive loss	$ (156,266)	$ (180,643)

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) - $ / shares	12 Months Ended
	May 31, 2023	May 31, 2022
Income Statement [Abstract]
Net loss per share - basic	$ (0.01)	$ (0.01)
Net loss per share - diluted	$ (0.01)	$ (0.01)
Weighted average number of common shares outstanding - basic	19,767,698	19,767,698
Weighted average number of common shares outstanding - diluted	19,767,698	19,767,698

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning balance, value at May. 31, 2021	$ 19,768	$ 2,655,236	$ 57,197	$ (4,692,022)	$ (1,959,821)
Beginning balance, shares at May. 31, 2021	19,767,698
Net loss and comprehensive loss				(180,643)	(180,643)
Ending balance, value at May. 31, 2022	$ 19,768	2,655,236	57,197	(4,872,665)	(2,140,464)
Ending balance, shares at May. 31, 2022	19,767,698
Net loss and comprehensive loss				(156,266)	(156,266)
Ending balance, value at May. 31, 2023	$ 19,768	$ 2,655,236	$ 57,197	$ (5,028,931)	$ (2,296,730)
Ending balance, shares at May. 31, 2023	19,767,698

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2

+ Details

XML 17 R7.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	May 31, 2023	May 31, 2022
Cash flows from operating activities
Net loss	$ (156,266)	$ (180,643)
Change in operating assets and liabilities
Increase in accounts payable and accrued liabilities - related party	120,000	120,000
Increase in accounts payable and accrued liabilities	(1,351)	(3,328)
Cash flows used in operating activities	(37,617)	(63,971)
Cash flows from investing activities	0	0
Cash flows from financing activities
Advances - related party	33,157	44,278
Repayment of advances - related party	(785)	(11,698)
Proceeds from the issuance of liability for unissued shares	0	0
Proceeds from loans payable - shareholders	4,992	31,610
Net cash provided by financing activities	37,364	64,190
Net change in cash	(253)	219
Cash, beginning of the period	259	40
Cash, end of the period	6	259
Supplemental Disclosure:
Cash paid for income taxes	0	0
Cash paid for interest	0	0
Non-cash Investing and Financing Activities:
Conversion of Accounts payable and accrued liabilities - related party to Promissory note - related party	0	429,121
Conversion of Advances - related party to Promissory note - related party	$ 0	$ 37,696

XML 18 R8.htm IDEA: XBRL DOCUMENT

Organization and Description of Business

12 Months Ended

May 31, 2023

Accounting Policies [Abstract]

Organization and Description of Business

Note 1 – Organization and Description of Business

XML 19 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

12 Months Ended

May 31, 2023

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

Principles of Consolidation

Going Concern

Cash and Cash Equivalents

The Company considers all highly liquid debt instruments with an original maturity of three months or less to be cash equivalents.

Use of Estimates

Foreign Currency Translation

ii)

income and expenses are translated at average exchange rates for the year ended May 31, 2023 of 1.00 US Dollar = 1.3351 Canadian Dollars and 1.00 US Dollar = 1.2632 Canadian Dollars (May 31, 2022);

iii)

Fair Value of Financial Instruments

☐

Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

☐

Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

Net Loss Per Share

Research and Development Costs

Software Development Costs

Website development costs are capitalized under the same criteria as our marketed software.

Impairment of Long-lived Assets

Commitments and Contingencies

Revenue Recognition

Gross Versus Net Revenue

During the years ended May 31, 2023 and 2022, the Company had revenue of $0 and $368, respectively. The Company earns a 10% commission on amounts reimbursed for eligible expenses.

Income Taxes

XML 20 R10.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements

12 Months Ended

May 31, 2023

Accounting Changes and Error Corrections [Abstract]

Recent Accounting Pronouncements

Note 3 – Recent Accounting Pronouncements

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479832/842-10-65-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479832/842-10-65-5

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483550/848-10-65-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479343/105-10-65-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480530/250-10-S99-6

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 250
-Publisher FASB
-URI https://asc.fasb.org//250/tableOfContent

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-SubTopic 20
-Topic 310
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481925/310-20-65-2

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-SubTopic 20
-Topic 310
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481925/310-20-65-2

+ Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

Related Party Transactions

12 Months Ended

May 31, 2023

Related Party Transactions

Note 4 – Related Party Transactions

Advances – Related Party

Loans Payable – Shareholders

Promissory Note – Related Party

Convertible Note Payable – Related Party

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

XML 22 R12.htm IDEA: XBRL DOCUMENT

Income Taxes

12 Months Ended

May 31, 2023

Income Tax Disclosure [Abstract]

Income Taxes

Note 5 – Income Taxes


	2023			2022

Net operating losses – U.S. parent:
Amount carried forward from prior years	$	(872,137	)	$	(859,324	)
Net operating losses (21% tax rate)		(32,815	)		(38,013	)
Accrued management compensation		25,200			25,200
Total		(879,752	)		(872,137	)
The Company’s deferred tax assets and liabilities consist primarily of the following:

Deferred taxes – U.S. Parent		(879,752	)		(872,137	)
Net operating losses – Canadian subsidiary:
Amount carried forward from prior years		(31,760	)		(31,760	)
Net operating losses		—			—
Deferred taxes – Canadian subsidiary		(31,760	)		(31,760	)

Total deferred tax assets		(911,512	)		(903,897	)
Less: valuation allowance		911,512			903,897
Total net deferred tax assets	$	—		$	—

During the years ended May 31, 2023 and 2022, the change in valuation allowance was an increase of $7,615 in 2023 and an increase of $12,813 in 2022.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

XML 23 R13.htm IDEA: XBRL DOCUMENT

Stockholders’ Deficit

12 Months Ended

May 31, 2023

Equity [Abstract]

Stockholders’ Deficit

Note 6 – Stockholders’ Deficit

Common Stock

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

XML 24 R14.htm IDEA: XBRL DOCUMENT

Contingencies and Commitments

12 Months Ended

May 31, 2023

Commitments and Contingencies Disclosure [Abstract]

Contingencies and Commitments

Note 7 – Contingencies and Commitments

The Company does not have long-term commitments for equipment purchases or leases. The Company presently operates from remote employment sites.

XML 25 R15.htm IDEA: XBRL DOCUMENT

Subsequent Events

12 Months Ended

May 31, 2023

Subsequent Events [Abstract]

Subsequent Events

Note 8 – Subsequent Events

The Company has evaluated all subsequent events through the date these financial statements were issued and no subsequent events occurred that required disclosure.

XML 26 R16.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

12 Months Ended

May 31, 2023

Accounting Policies [Abstract]

Principles of Consolidation

Principles of Consolidation

Going Concern

Going Concern

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid debt instruments with an original maturity of three months or less to be cash equivalents.

Use of Estimates

Use of Estimates

Foreign Currency Translation

Foreign Currency Translation

ii)

income and expenses are translated at average exchange rates for the year ended May 31, 2023 of 1.00 US Dollar = 1.3351 Canadian Dollars and 1.00 US Dollar = 1.2632 Canadian Dollars (May 31, 2022);

iii)

Fair Value of Financial Instruments

Fair Value of Financial Instruments

☐

Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

☐

Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

Net Loss Per Share

Net Loss Per Share

Research and Development Costs

Research and Development Costs

Software Development Costs

Software Development Costs

Website development costs are capitalized under the same criteria as our marketed software.

Impairment of Long-lived Assets

Impairment of Long-lived Assets

Commitments and Contingencies

Commitments and Contingencies

Revenue Recognition

Revenue Recognition

Gross Versus Net Revenue

Gross Versus Net Revenue

During the years ended May 31, 2023 and 2022, the Company had revenue of $0 and $368, respectively. The Company earns a 10% commission on amounts reimbursed for eligible expenses.

Income Taxes

Income Taxes

XML 27 R17.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

12 Months Ended

May 31, 2023

Income Tax Disclosure [Abstract]

Schedule of deferred tax assets and liabilities


	2023			2022

Net operating losses – U.S. parent:
Amount carried forward from prior years	$	(872,137	)	$	(859,324	)
Net operating losses (21% tax rate)		(32,815	)		(38,013	)
Accrued management compensation		25,200			25,200
Total		(879,752	)		(872,137	)
The Company’s deferred tax assets and liabilities consist primarily of the following:

Deferred taxes – U.S. Parent		(879,752	)		(872,137	)
Net operating losses – Canadian subsidiary:
Amount carried forward from prior years		(31,760	)		(31,760	)
Net operating losses		—			—
Deferred taxes – Canadian subsidiary		(31,760	)		(31,760	)

Total deferred tax assets		(911,512	)		(903,897	)
Less: valuation allowance		911,512			903,897
Total net deferred tax assets	$	—		$	—

XML 28 R18.htm IDEA: XBRL DOCUMENT

Organization and Description of Business (Details Narrative) - Tiempo De Mexico Ltd [Member] - Common Stocks [Member]	May 31, 2005 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares issued for acquisition \| shares	5,000,000
Share issued price \| $ / shares	$ 0.001

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

XML 29 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative)	12 Months Ended
	May 31, 2023 USD ($) shares	May 31, 2022 USD ($)	May 31, 2021 USD ($)
Net loss	$ 156,266	$ 180,643
Cash used in operating activities	37,617	63,971
Stockholders' deficit	2,296,730	2,140,464	$ 1,959,821
Research and development expenses	6,528	25,642
Revenue	$ 0	$ 368
Convertible Notes Payable Related Party [Member]
Antidilutive shares \| shares	10,587,600
UNITED STATES
Foreign currency exchange rate translation	1.00	1.00
UNITED STATES \| Income And Expenses [Member]
Foreign currency exchange rate translation	1.00	1.00
Canada Dollars [Member]
Foreign currency exchange rate translation	1.3605	1.2632
Canada Dollars [Member] \| Income And Expenses [Member]
Foreign currency exchange rate translation	1.3351	1.2632
U S D [Member]
Foreign currency exchange rate translation	1.00	1.00
G B P [Member]
Foreign currency exchange rate translation	0.593	0.7925

XML 30 R20.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	May 31, 2023	May 31, 2022
Related Party Transaction [Line Items]
Consulting services	$ 120,442	$ 120,785
Advances - related party	33,157	44,278
Repayment of advances to related party	785	11,698
Loans Payable, Current	173,067	168,075
Proceeds from Loans	4,992	31,610
Repayment of loans payable - shareholder	0	0
Note payable - related party	466,817	466,817
Convertible note payable related party	1,058,760	1,058,760
Promissory Note Related Party [Member]
Related Party Transaction [Line Items]
Accounts payable and accrued liabilities related party		429,121
Advance related party		37,696
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Consulting services	120,000	120,000
Advances - related party	33,157	44,278
Repayment of advances to related party	$ 785	11,698
Convertible note conversion price	$ 0.10
Common stock shares issuable upon conversion of debt	10,587,600
Tom Zapatinas [Member]
Related Party Transaction [Line Items]
Accounts payable and accrued liabilities related party	$ 240,000	120,000
Advance related party	$ 64,952	$ 32,580

XML 31 R21.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD ($)	May 31, 2023	May 31, 2022
Net operating losses	$ (4,189,000)
Total deferred tax asset	(911,512)	$ (903,897)
Less: valuation allowance	911,512	903,897
Total net deferred tax assets	0	0
Parent Company [Member]
Amount carried forward from prior years	(872,137)	(859,324)
Net operating losses	(32,815)	(38,013)
Accrued management compensation	25,200	25,200
Total	(879,752)	(872,137)
Total deferred tax asset	(879,752)	(872,137)
Subsidiaries [Member]
Amount carried forward from prior years	(31,760)	(31,760)
Net operating losses	0	0
Total deferred tax asset	$ (31,760)	$ (31,760)

XML 32 R22.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
Income Taxes (Details Narrative) - USD ($)	May 31, 2023	May 31, 2022
Income Tax Disclosure [Abstract]
Operating loss carryforwards limitations on use	Tax years 2008 through 2023 are open for examination by taxing authorities.
Net operating losses carryforwad	$ 4,189,000
Change in valuation allowance	$ 7,615	$ 12,813

XML 33 R23.htm IDEA: XBRL DOCUMENT

Stockholders’ Deficit (Details Narrative) - $ / shares	May 31, 2023	May 31, 2022
Equity [Abstract]
Common stock par value per share	$ 0.001	$ 0.001
Common stock shares authorized	75,000,000	75,000,000
Common stock shares issued	19,767,698	19,767,698
Common stock shares outstanding	19,767,698	19,767,698

XML 34 paxh53123_htm.xml IDEA: XBRL DOCUMENT 0001350156 2022-06-01 2023-05-31 0001350156 2022-11-30 0001350156 2023-08-30 0001350156 2023-05-31 0001350156 2022-05-31 0001350156 2021-06-01 2022-05-31 0001350156 us-gaap:CommonStockMember 2021-05-31 0001350156 us-gaap:AdditionalPaidInCapitalMember 2021-05-31 0001350156 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-05-31 0001350156 us-gaap:RetainedEarningsMember 2021-05-31 0001350156 2021-05-31 0001350156 us-gaap:CommonStockMember 2022-05-31 0001350156 us-gaap:AdditionalPaidInCapitalMember 2022-05-31 0001350156 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-05-31 0001350156 us-gaap:RetainedEarningsMember 2022-05-31 0001350156 us-gaap:CommonStockMember 2021-06-01 2022-05-31 0001350156 us-gaap:AdditionalPaidInCapitalMember 2021-06-01 2022-05-31 0001350156 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-01 2022-05-31 0001350156 us-gaap:RetainedEarningsMember 2021-06-01 2022-05-31 0001350156 us-gaap:CommonStockMember 2022-06-01 2023-05-31 0001350156 us-gaap:AdditionalPaidInCapitalMember 2022-06-01 2023-05-31 0001350156 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-01 2023-05-31 0001350156 us-gaap:RetainedEarningsMember 2022-06-01 2023-05-31 0001350156 us-gaap:CommonStockMember 2023-05-31 0001350156 us-gaap:AdditionalPaidInCapitalMember 2023-05-31 0001350156 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-05-31 0001350156 us-gaap:RetainedEarningsMember 2023-05-31 0001350156 paxh:TiempoDeMexicoLtdMember paxh:CommonStocksMember 2005-05-30 2005-05-31 0001350156 paxh:TiempoDeMexicoLtdMember paxh:CommonStocksMember 2005-05-31 0001350156 country:US 2023-05-31 0001350156 paxh:CanadaDollarsMember 2023-05-31 0001350156 paxh:USDMember 2023-05-31 0001350156 paxh:GBPMember 2023-05-31 0001350156 country:US 2022-05-31 0001350156 paxh:CanadaDollarsMember 2022-05-31 0001350156 paxh:USDMember 2022-05-31 0001350156 paxh:GBPMember 2022-05-31 0001350156 country:US paxh:IncomeAndExpensesMember 2023-05-31 0001350156 paxh:CanadaDollarsMember paxh:IncomeAndExpensesMember 2023-05-31 0001350156 country:US paxh:IncomeAndExpensesMember 2022-05-31 0001350156 paxh:CanadaDollarsMember paxh:IncomeAndExpensesMember 2022-05-31 0001350156 paxh:ConvertibleNotesPayableRelatedPartyMember 2022-06-01 2023-05-31 0001350156 paxh:TomZapatinasMember 2023-05-31 0001350156 paxh:TomZapatinasMember 2022-05-31 0001350156 srt:ChiefExecutiveOfficerMember 2022-06-01 2023-05-31 0001350156 srt:ChiefExecutiveOfficerMember 2021-06-01 2022-05-31 0001350156 paxh:PromissoryNoteRelatedPartyMember 2022-05-31 0001350156 srt:ChiefExecutiveOfficerMember 2023-05-31 0001350156 srt:ParentCompanyMember 2023-05-31 0001350156 srt:ParentCompanyMember 2022-05-31 0001350156 srt:SubsidiariesMember 2023-05-31 0001350156 srt:SubsidiariesMember 2022-05-31 iso4217:USD shares iso4217:USD shares pure 0001350156 false 2023 FY

10-K true 2023-05-31 --05-31 false 000-53490 PREAXIA HEALTH CARE PAYMENT SYSTEMS INC. NV 20-4395271 PO Box 34075 Westbrook PO 1610-37th Street S.W. Calgary AB T3C 3W2 403 850-4120 Common Stock, $0.001 par value No No Yes false Yes Non-accelerated Filer true false false 602725 19767698 6580 GreenGrowthCPAs Los Angeles, California

259

158348

159699

240000 120000 64952 32580 173067 168075

134792

466817 466817

1058760

2296736

2140723

2296736

2140723

0.001

75000000

19767698

19768

2655236

57197

-5028931

-4872665

-2296730

-2140464

259

368

120442 120785

15504

17576

13792

17008

6528

25642

156266

181011

-156266

-180643

-156266

-180643

-0.01

19767698

19768

2655236

57197

-4692022

-1959821

-180643

19767698

19768

2655236

57197

-4872665

-2140464

-156266

19767698

19768

2655236

57197

-5028931

-2296730

-156266

-180643

120000

-1351

-3328

-37617

-63971

33157

44278

785

11698

0 0

4992

31610

37364

64190

-253

219

259

0 429121 0 37696

<p id="xdx_80D_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_z8HJWvtBC24e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Note 1 – Organization and Description of Business PreAxia Health Care Payment Systems Inc. (the “Company” or “PreAxia”) was incorporated on April 3, 2000 in the State of Nevada. On May 31, 2005, the Company acquired all of the outstanding stock of Tiempo de Mexico Ltd. (“Tiempo”) in exchange for <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20050530__20050531__us-gaap--PlanNameAxis__custom--TiempoDeMexicoLtdMember__us-gaap--StatementClassOfStockAxis__custom--CommonStocksMember_pdd" title="Shares issued for acquisition">5,000,000 shares of the common stock of the Company with a par value of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20050531__us-gaap--PlanNameAxis__custom--TiempoDeMexicoLtdMember__us-gaap--StatementClassOfStockAxis__custom--CommonStocksMember_zKc24ucgDN2l" title="Share issued price">0.001. The Company had no operations prior to the date of the aforementioned acquisition. The business objective of the Company is the development, distribution, marketing and sale of health care payment processing services and products. The Company has realized only nominal revenues from its planned operations. The operations of the Company are expected to be primarily undertaken by its wholly-owned subsidiary, PreAxia Health Care Payment Ltd. (“PreAxia Payment”), incorporated pursuant to the laws of the Province of Alberta on November 26, 2015. PreAxia Payment is in the process of developing an online access system creating a health spending account that will facilitate card payment and processing services to third-party administrators, insurance companies and others.

5000000

0.001

Note 2 – Summary of Significant Accounting Policies This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s consolidated financial statements. The consolidated financial statements and notes are representations of the Company’s management who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the consolidated financial statements, which are stated in U.S. Dollars. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries (i) PreAxia Health Care Payment Systems Inc., incorporated pursuant to the laws of the Province of Alberta on January 28, 2008 (ii) PreAxia Canada Inc., incorporated pursuant to the laws of the Province of Alberta on January 28, 2008 and (iii) PreAxia Health Care Payment Ltd., incorporated pursuant to the laws of the Province of Alberta on November 26, 2015 (collectively, the “Subsidiaries”). All inter-company accounts and transactions have been eliminated in consolidation. Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. During the year ended May 31, 2023, the Company incurred a net loss of $156,266 and used cash in operating activities of $37,617, and on May 31, 2023, had a stockholders’ deficit of $2,296,730. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the consolidated financial statements are issued. The Company’s consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty should we be unable to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to develop additional sources of capital and to ultimately achieve profitable operations. Currently, the Company does not have significant cash or other material assets, nor does it have operations or a source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The Company’s officers or principal shareholders are committed to making advances or loans to pay for certain legal, accounting, and administrative costs. The Company hopes to be able to attract suitable investors for our business plan, which will not require us to use our cash. There can be no assurance that the Company will be successful in this situation. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing. Cash and Cash Equivalents The Company considers all highly liquid debt instruments with an original maturity of three months or less to be cash equivalents. Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in these consolidated financial statements and accompanying notes. Although these estimates are based on management’s knowledge of current events and actions that our company may undertake in the future, actual results could differ from those estimates. Foreign Currency Translation The functional currency of the Company is the United States dollar. The functional currency of the Subsidiaries is the Canadian dollar. Assets and liabilities in the accompanying consolidated financial statements are translated into United States dollars at the exchange rate in effect at the balance sheet date and capital accounts are translated at historical rates. Income statement accounts are translated at the average rates of exchange prevailing during the period. Translation adjustments arising from the use of differing exchange rates from period to period are included in the accumulated other comprehensive income (loss) account in stockholders’ deficit. Transactions undertaken in currencies other than the functional currency of the entity are translated using the exchange rate in effect as of the transaction date. Any transaction exchange gains and losses are included in the statement of operations and comprehensive loss. The Company's reporting currency is the U.S. dollar. All transactions initiated in Canadian Dollars are translated into U.S. dollars in accordance with Accounting Standards Codification ("ASC") 830-30, "Translation of Financial Statements," as follows: <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.5in">i)</td><td style="text-align: justify">assets and liabilities are translated at the closing rate at the date of the balance sheet of 1.00 US Dollar =<span id="xdx_901_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20230531__us-gaap--GeographicDistributionAxis__custom--CanadaDollarsMember_zbdhqCEh6EMk" title="Foreign currency exchange rate translation">1.3605 Canadian Dollars (May 31, 2023), 1.00 USD Dollar=0.593 GBP, and 1.00 US Dollar=<span id="xdx_904_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20220531__us-gaap--GeographicDistributionAxis__custom--CanadaDollarsMember_zkGdRCLf3ZS6" title="Foreign currency exchange rate translation">1.2632 Canadian Dollars (May 31, 2022), 1.00 USD Dollar=0.7925 GBP;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.5in">ii)</td><td style="text-align: justify">income and expenses are translated at average exchange rates for the year ended May 31, 2023 of <span id="xdx_908_eus-gaap--ForeignCurrencyExchangeRateTranslation1_c20230531__us-gaap--GeographicDistributionAxis__country--US__us-gaap--IncomeStatementLocationAxis__custom--IncomeAndExpensesMember_zIWPmXOeCIz5" title="Foreign currency exchange rate translation">1.00 US Dollar = <span id="xdx_90A_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20230531__us-gaap--GeographicDistributionAxis__custom--CanadaDollarsMember__us-gaap--IncomeStatementLocationAxis__custom--IncomeAndExpensesMember_z4FVziRhAJm9" title="Foreign currency exchange rate translation">1.3351 Canadian Dollars and <span id="xdx_90E_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20220531__us-gaap--GeographicDistributionAxis__country--US__us-gaap--IncomeStatementLocationAxis__custom--IncomeAndExpensesMember_zX9U1GEV4lkd" title="Foreign currency exchange rate translation">1.00 US Dollar = <span id="xdx_90E_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20220531__us-gaap--GeographicDistributionAxis__custom--CanadaDollarsMember__us-gaap--IncomeStatementLocationAxis__custom--IncomeAndExpensesMember_z9k29qktoCnj" title="Foreign currency exchange rate translation">1.2632 Canadian Dollars (May 31, 2022);</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.5in">iii)</td><td style="text-align: justify">all resulting exchange differences are recognized as other comprehensive income, a separate component of equity. The exchange differences during the year ended May 31, 2023 and 2022 were insignificant and no amounts have been recorded.</td></tr></table> Fair Value of Financial Instruments The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Management uses a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below: <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">☐</td> <td style="text-align: justify">Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">☐</td> <td style="text-align: justify">Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">☐</td> <td style="text-align: justify">Level 3 - Inputs that are both significant to the fair value measurement and unobservable.</td></tr> </table> The fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of May 31, 2023 and, 2022. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. Net Loss Per Share Net loss per share of common stock is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. The Company has <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220601__20230531__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesPayableRelatedPartyMember_zX78MY68h67c" title="Antidilutive shares">10,587,600 shares of potential common stock equivalents for convertible note payable – related party outstanding during the periods ended May 31, 2023 and 2022, which have been excluded from the loss per share computation as their effect would have been anti-dilutive due to net losses. Research and Development Costs The Company expenses research and development costs as incurred in accordance with FASB ASC 730 “Research and Development.” During the years ended May 31, 2023 and 2022, we incurred $6,528 and $25,642, respectively, in research and development expenses. Software Development Costs The Company accounts for software development costs in accordance with several accounting pronouncements, including FASB ASC 730, “Research and Development,” FASB ASC 350-40, “Internal-Use Software,” FASB 985-20, “Costs of Computer Software to be Sold, Leased, or Marketed” and FASB ASC 350-50, “Website Development Costs.” Costs incurred during the period of planning and design, prior to the period determining technological feasibility, for all software developed for use internal and external, has been charged to operations in the period incurred as research and development costs. Additionally, costs incurred after determination of readiness for market have been expensed as research and development. The Company will capitalize certain costs in the development of our proprietary software (computer software to be sold, leased or licensed) for the period after technological feasibility was determined and prior to our marketing and initial sales. Website development costs are capitalized under the same criteria as our marketed software. Impairment of Long-lived Assets Long-lived assets such as property, equipment and identifiable intangibles are reviewed for impairment whenever facts and circumstances indicate that the carrying value may not be recoverable. When required, impairment losses on assets to be held and used are recognized based on the fair value of the asset. The fair value is determined based on estimates of future cash flows, market value of similar assets, if available, or independent appraisals, if required. If the carrying amount of the long-lived asset is not recoverable from its undiscounted cash flows, an impairment loss is recognized for the difference between the carrying amount and fair value of the asset. When fair values are not available, the Company estimates fair value using the expected future cash flows discounted at a rate commensurate with the risk associated with the recovery of the assets. We did not recognize any impairment losses for any periods presented. Commitments and Contingencies The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. Revenue Recognition In accordance with ASC 606, “Revenue from Contracts with Customers,” revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation. Gross Versus Net Revenue ASC 606 provides guidance on proper recognition of principal versus agent considerations which is used to determine gross versus net revenue recognition. Under ASC 606, the core objective of the guidance on gross versus net revenue recognition is to help determine whether an entity is a principal or an agent in a transaction. In general, the primary difference between these two is the performance obligation being satisfied. The principal has a performance obligation to provide the desired goods or services to the end customer, whereas the agent arranges for the principal to provide the desired goods or services. Additionally, a fundamental characteristic of a principal in a transaction is control. A principal substantively controls the goods and services before they are transferred to the customer as well as controlling the price of the good or service being provided. An agent normally receives a commission or fee for these activities. In addition to control, the level at which an entity controls the price of the good or service being transferred determines principal versus agent status. The more discretion over setting price a company has in providing the good or service, the more likely they are considered a principal rather than an agent. Under the guidance when another party is involved in providing a good or service to a customer, an entity is a principal if the entity obtains control of the asset or right to a service performed by the other party. The Company provides administrative services for Health Spending Accounts sponsored by employers (the “customer”). The Company does not take possession of goods or control the services provided as the employees of the customer are free to determine their health care provider. As such, the Company records revenue net of reimbursements to employees. The Company’s services to the customer consist of reviewing medical costs for eligibility and reimbursing employees for eligible costs. During the years ended May 31, 2023 and 2022, the Company had revenue of $0 and $368, respectively. The Company earns a 10% commission on amounts reimbursed for eligible expenses. Income Taxes The Company follows Section 740-10-30 of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the fiscal year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Income and Comprehensive Income in the period that includes the enactment date. The Company follows section 740-10-25 of the FASB Accounting Standards Codification (“Section 740-10-25”) with regards to uncertain income tax positions. Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures.

Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries (i) PreAxia Health Care Payment Systems Inc., incorporated pursuant to the laws of the Province of Alberta on January 28, 2008 (ii) PreAxia Canada Inc., incorporated pursuant to the laws of the Province of Alberta on January 28, 2008 and (iii) PreAxia Health Care Payment Ltd., incorporated pursuant to the laws of the Province of Alberta on November 26, 2015 (collectively, the “Subsidiaries”). All inter-company accounts and transactions have been eliminated in consolidation.

Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. During the year ended May 31, 2023, the Company incurred a net loss of $156,266 and used cash in operating activities of $37,617, and on May 31, 2023, had a stockholders’ deficit of $2,296,730. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the consolidated financial statements are issued. The Company’s consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty should we be unable to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to develop additional sources of capital and to ultimately achieve profitable operations. Currently, the Company does not have significant cash or other material assets, nor does it have operations or a source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The Company’s officers or principal shareholders are committed to making advances or loans to pay for certain legal, accounting, and administrative costs. The Company hopes to be able to attract suitable investors for our business plan, which will not require us to use our cash. There can be no assurance that the Company will be successful in this situation. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing.

-156266

-37617

-2296730

Cash and Cash Equivalents The Company considers all highly liquid debt instruments with an original maturity of three months or less to be cash equivalents.

Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in these consolidated financial statements and accompanying notes. Although these estimates are based on management’s knowledge of current events and actions that our company may undertake in the future, actual results could differ from those estimates.

Foreign Currency Translation The functional currency of the Company is the United States dollar. The functional currency of the Subsidiaries is the Canadian dollar. Assets and liabilities in the accompanying consolidated financial statements are translated into United States dollars at the exchange rate in effect at the balance sheet date and capital accounts are translated at historical rates. Income statement accounts are translated at the average rates of exchange prevailing during the period. Translation adjustments arising from the use of differing exchange rates from period to period are included in the accumulated other comprehensive income (loss) account in stockholders’ deficit. Transactions undertaken in currencies other than the functional currency of the entity are translated using the exchange rate in effect as of the transaction date. Any transaction exchange gains and losses are included in the statement of operations and comprehensive loss. The Company's reporting currency is the U.S. dollar. All transactions initiated in Canadian Dollars are translated into U.S. dollars in accordance with Accounting Standards Codification ("ASC") 830-30, "Translation of Financial Statements," as follows: <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.5in">i)</td><td style="text-align: justify">assets and liabilities are translated at the closing rate at the date of the balance sheet of 1.00 US Dollar =<span id="xdx_901_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20230531__us-gaap--GeographicDistributionAxis__custom--CanadaDollarsMember_zbdhqCEh6EMk" title="Foreign currency exchange rate translation">1.3605 Canadian Dollars (May 31, 2023), 1.00 USD Dollar=0.593 GBP, and 1.00 US Dollar=<span id="xdx_904_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20220531__us-gaap--GeographicDistributionAxis__custom--CanadaDollarsMember_zkGdRCLf3ZS6" title="Foreign currency exchange rate translation">1.2632 Canadian Dollars (May 31, 2022), 1.00 USD Dollar=0.7925 GBP;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.5in">ii)</td><td style="text-align: justify">income and expenses are translated at average exchange rates for the year ended May 31, 2023 of <span id="xdx_908_eus-gaap--ForeignCurrencyExchangeRateTranslation1_c20230531__us-gaap--GeographicDistributionAxis__country--US__us-gaap--IncomeStatementLocationAxis__custom--IncomeAndExpensesMember_zIWPmXOeCIz5" title="Foreign currency exchange rate translation">1.00 US Dollar = <span id="xdx_90A_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20230531__us-gaap--GeographicDistributionAxis__custom--CanadaDollarsMember__us-gaap--IncomeStatementLocationAxis__custom--IncomeAndExpensesMember_z4FVziRhAJm9" title="Foreign currency exchange rate translation">1.3351 Canadian Dollars and <span id="xdx_90E_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20220531__us-gaap--GeographicDistributionAxis__country--US__us-gaap--IncomeStatementLocationAxis__custom--IncomeAndExpensesMember_zX9U1GEV4lkd" title="Foreign currency exchange rate translation">1.00 US Dollar = <span id="xdx_90E_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_c20220531__us-gaap--GeographicDistributionAxis__custom--CanadaDollarsMember__us-gaap--IncomeStatementLocationAxis__custom--IncomeAndExpensesMember_z9k29qktoCnj" title="Foreign currency exchange rate translation">1.2632 Canadian Dollars (May 31, 2022);</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.5in">iii)</td><td style="text-align: justify">all resulting exchange differences are recognized as other comprehensive income, a separate component of equity. The exchange differences during the year ended May 31, 2023 and 2022 were insignificant and no amounts have been recorded.</td></tr></table>

1.00

1.3605

1.00

0.593

1.00

1.2632

1.00

0.7925

1.00

1.3351

1.00

1.2632

Fair Value of Financial Instruments The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Management uses a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below: <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">☐</td> <td style="text-align: justify">Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">☐</td> <td style="text-align: justify">Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">☐</td> <td style="text-align: justify">Level 3 - Inputs that are both significant to the fair value measurement and unobservable.</td></tr> </table> The fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of May 31, 2023 and, 2022. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

Net Loss Per Share Net loss per share of common stock is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. The Company has <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220601__20230531__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesPayableRelatedPartyMember_zX78MY68h67c" title="Antidilutive shares">10,587,600 shares of potential common stock equivalents for convertible note payable – related party outstanding during the periods ended May 31, 2023 and 2022, which have been excluded from the loss per share computation as their effect would have been anti-dilutive due to net losses.

10587600

Research and Development Costs The Company expenses research and development costs as incurred in accordance with FASB ASC 730 “Research and Development.” During the years ended May 31, 2023 and 2022, we incurred $6,528 and $25,642, respectively, in research and development expenses.

6528

25642

Software Development Costs The Company accounts for software development costs in accordance with several accounting pronouncements, including FASB ASC 730, “Research and Development,” FASB ASC 350-40, “Internal-Use Software,” FASB 985-20, “Costs of Computer Software to be Sold, Leased, or Marketed” and FASB ASC 350-50, “Website Development Costs.” Costs incurred during the period of planning and design, prior to the period determining technological feasibility, for all software developed for use internal and external, has been charged to operations in the period incurred as research and development costs. Additionally, costs incurred after determination of readiness for market have been expensed as research and development. The Company will capitalize certain costs in the development of our proprietary software (computer software to be sold, leased or licensed) for the period after technological feasibility was determined and prior to our marketing and initial sales. Website development costs are capitalized under the same criteria as our marketed software.

Impairment of Long-lived Assets Long-lived assets such as property, equipment and identifiable intangibles are reviewed for impairment whenever facts and circumstances indicate that the carrying value may not be recoverable. When required, impairment losses on assets to be held and used are recognized based on the fair value of the asset. The fair value is determined based on estimates of future cash flows, market value of similar assets, if available, or independent appraisals, if required. If the carrying amount of the long-lived asset is not recoverable from its undiscounted cash flows, an impairment loss is recognized for the difference between the carrying amount and fair value of the asset. When fair values are not available, the Company estimates fair value using the expected future cash flows discounted at a rate commensurate with the risk associated with the recovery of the assets. We did not recognize any impairment losses for any periods presented.

Commitments and Contingencies The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.

Revenue Recognition In accordance with ASC 606, “Revenue from Contracts with Customers,” revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.

Gross Versus Net Revenue ASC 606 provides guidance on proper recognition of principal versus agent considerations which is used to determine gross versus net revenue recognition. Under ASC 606, the core objective of the guidance on gross versus net revenue recognition is to help determine whether an entity is a principal or an agent in a transaction. In general, the primary difference between these two is the performance obligation being satisfied. The principal has a performance obligation to provide the desired goods or services to the end customer, whereas the agent arranges for the principal to provide the desired goods or services. Additionally, a fundamental characteristic of a principal in a transaction is control. A principal substantively controls the goods and services before they are transferred to the customer as well as controlling the price of the good or service being provided. An agent normally receives a commission or fee for these activities. In addition to control, the level at which an entity controls the price of the good or service being transferred determines principal versus agent status. The more discretion over setting price a company has in providing the good or service, the more likely they are considered a principal rather than an agent. Under the guidance when another party is involved in providing a good or service to a customer, an entity is a principal if the entity obtains control of the asset or right to a service performed by the other party. The Company provides administrative services for Health Spending Accounts sponsored by employers (the “customer”). The Company does not take possession of goods or control the services provided as the employees of the customer are free to determine their health care provider. As such, the Company records revenue net of reimbursements to employees. The Company’s services to the customer consist of reviewing medical costs for eligibility and reimbursing employees for eligible costs. During the years ended May 31, 2023 and 2022, the Company had revenue of $0 and $368, respectively. The Company earns a 10% commission on amounts reimbursed for eligible expenses. 0 368

Income Taxes The Company follows Section 740-10-30 of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the fiscal year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Income and Comprehensive Income in the period that includes the enactment date. The Company follows section 740-10-25 of the FASB Accounting Standards Codification (“Section 740-10-25”) with regards to uncertain income tax positions. Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures.

Note 3 – Recent Accounting Pronouncements The Company reviews new accounting standards as issued or updated. No new standards or updates had any material effect on these consolidated financial statements. The accounting pronouncements issued subsequent to the date of these consolidated financial statements that were considered significant by management were evaluated for the potential effect on these consolidated financial statements. Management does not believe any of the subsequent pronouncements will have a material effect on these consolidated financial statements as presented.

Note 4 – Related Party Transactions As of May 31, 2023 and 2022, accounts payable and accrued liabilities – related party due to Tom Zapatinas totaled $<span id="xdx_90F_ecustom--AccountsPayableAndAccruedLiabilitiesRelatedParty_iI_pp0p0_c20230531__us-gaap--RelatedPartyTransactionAxis__custom--TomZapatinasMember_zsidF1sIm95" title="Accounts payable and accrued liabilities - related party">240,000 and $<span id="xdx_902_ecustom--AccountsPayableAndAccruedLiabilitiesRelatedParty_iI_pp0p0_c20220531__us-gaap--RelatedPartyTransactionAxis__custom--TomZapatinasMember_zTqoC81oKEya" title="Accounts payable and accrued liabilities - related party">120,000, respectively. During the years ended May 31, 2023 and 2022, Tom Zapatinas, the Chief Executive Officer and Director of the Company, earned $120,000 and $120,000, respectively, for consulting services provided to the Company. On May 31, 2022, accounts payable and accrued liabilities – related party of $<span id="xdx_90D_ecustom--AccountsPayableAndAccruedLiabilitiesRelatedParty_iI_pp0p0_c20220531__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteRelatedPartyMember_z2wGKxPpTjbg" title="Accounts payable and accrued liabilities - related party">429,121 was settled by issuing promissory note – related party below. Advances – Related Party As of May 31, 2023 and 2022, advances payable due to Tom Zapatinas totaled $64,952 and $32,580, respectively. During the year ended May 31, 2023 and 2022, Tom Zapatinas, the Chief Executive Officer and a Director of the Company, advanced the Company $<span id="xdx_90B_eus-gaap--ProceedsFromRelatedPartyDebt_pp0p0_c20220601__20230531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zWvKG0M1Rhx8" title="Advances - related party">33,157 and $<span id="xdx_90F_eus-gaap--ProceedsFromRelatedPartyDebt_pp0p0_c20210601__20220531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zba1vyNAwFld" title="Advances - related party">44,278, respectively, in cash and was repaid $<span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_pp0p0_c20220601__20230531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zY6i61mk8dJd" title="Repayment of advances to related party">785 and $<span id="xdx_904_eus-gaap--RepaymentsOfRelatedPartyDebt_pp0p0_c20210601__20220531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zWZcwXh9OzN9" title="Repayment of advances to related party">11,698, respectively, in cash. On May 31, 2022, advances – related party of $37,696 was settled by issuing promissory note – related party below. Loans Payable – Shareholders As of May 31, 2023 and 2022, loans payable - shareholders are $173,067 and $168,075, respectively. Loans payable – shareholders are unsecured, non-interest bearing and due on demand. During the years ended May 31, 2023 and 2022, the Company was advanced $4,992 and $31,610, respectively, in cash, and was repaid $0 and $0, respectively, in cash. Promissory Note – Related Party As of May 31, 2023 and 2022, promissory note - related party of $466,817 and $466,817, respectively, is due to Tom Zapatinas, the Chief Executive Officer and a Director of the Company. The Note is non-interest bearing, unsecured and payable on demand. The note payable – related party was issued on May 31, 2022, to settle accounts payable and accrued liabilities – related party of $<span id="xdx_90E_ecustom--AccountsPayableAndAccruedLiabilitiesRelatedParty_iI_pp0p0_c20220531__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteRelatedPartyMember_zdayWyGfZwk9" title="Accounts payable and accrued liabilities related party">429,121 and advance – related party of $37,696. Convertible Note Payable – Related Party As of May 31, 2023 and 2022, convertible note payable - related party of $1,058,760 is due to Tom Zapatinas, the Chief Executive Officer and a Director of the Company. The Note is non-interest bearing, unsecured, payable on demand and convertible in whole or in part into shares of common stock of the Company at a conversion price of $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20230531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zPMVQw40Ke73" title="Convertible note conversion price">0.10 per share, which equates to <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_c20220601__20230531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zM8ZvyRiXr42" title="Common stock shares issuable upon conversion of debt">10,587,600 shares.

240000 120000 120000 120000 429121 64952 32580

33157

44278

785

11698

37696

173067

168075

4992

31610

0 0

466817

429121 37696

1058760

0.10

10587600

Note 5 – Income Taxes As of May 31, 2023, the Company is in arrears on filing its statutory income tax returns. Tax years 2008 through 2023 are open for examination by taxing authorities. The Company has incurred substantial net operating losses of approximately $4,189,000 since January 28, 2008 (Date of Inception). <table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zbmc5qFVzVNg" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Schedule of deferred tax assets and liabilities</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net operating losses – U.S. parent:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left">Amount carried forward from prior years</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--DeferredTaxAssetsAmountCarriedForwardFromPriorYears_iI_pp0p0_c20230531__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zA1HjLP614r" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Amount carried forward from prior years">(872,137</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--DeferredTaxAssetsAmountCarriedForwardFromPriorYears_c20220531__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Amount carried forward from prior years">(859,324</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net operating losses (21% tax rate)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--OperatingLossCarryforwards_iNI_pp0p0_di_c20230531__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zRdHorOLRQHg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net operating losses (21% tax rate)">(32,815</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingLossCarryforwards_iNI_pp0p0_di_c20220531__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zzaYhwsm4jPi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net operating losses (21% tax rate)">(38,013</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued management compensation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c20230531__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued management compensation">25,200</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c20220531__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued management compensation">25,200</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Total</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_c20230531__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">(879,752</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_c20220531__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">(872,137</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company’s deferred tax assets and liabilities consist primarily of the following:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> Deferred taxes – U.S. Parent</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--DeferredTaxAssetsGross_iNI_di_c20230531__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zZDlTW8NrQle" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred tax asset">(879,752</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--DeferredTaxAssetsGross_iNI_di_c20220531__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zrDnyaK1N69h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred tax asset">(872,137</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net operating losses – Canadian subsidiary:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amount carried forward from prior years</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_ecustom--DeferredTaxAssetsAmountCarriedForwardFromPriorYears_c20230531__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amount carried forward from prior years">(31,760</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--DeferredTaxAssetsAmountCarriedForwardFromPriorYears_c20220531__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amount carried forward from prior years">(31,760</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net operating losses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--OperatingLossCarryforwards_iNI_di0_c20230531__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zqjOIxEk4axd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net operating losses">— </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLossCarryforwards_iNI_di0_c20220531__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zmNa1csIvX5c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net operating losses">— </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> Deferred taxes – Canadian subsidiary</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsGross_iNI_pp0p0_di_c20230531__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zkt4KqVYHRNa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred tax asset">(31,760</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--DeferredTaxAssetsGross_iNI_pp0p0_di_c20220531__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zsKyOqNPPc0b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred tax asset">(31,760</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsGross_iNI_di_c20230531_zFWahSPGSF4a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred tax asset">(911,512</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--DeferredTaxAssetsGross_iNI_di_c20220531_zzbnRaSyCSL1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred tax asset">(903,897</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Less: valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20230531_zFNqMvLU9lm7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: valuation allowance">911,512</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20220531_zk2oDSYh9sF1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: valuation allowance">903,897</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> Total net deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--DeferredTaxAssetsNet_iI_d0_c20230531_zw4cTGiafpUg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total net deferred tax assets">— </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--DeferredTaxAssetsNet_iI_d0_c20220531_zi933T7hlL89" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total net deferred tax assets">— </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> During the years ended May 31, 2023 and 2022, the change in valuation allowance was an increase of $7,615 in 2023 and an increase of $12,813 in 2022. The Company has no tax positions at May 31, 2023 and 2022 for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. No such interest or penalties were recognized during the period presented. The Company had no accruals for interest and penalties at May 31, 2023 and 2022.

Tax years 2008 through 2023 are open for examination by taxing authorities.

4189000

<table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zbmc5qFVzVNg" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Schedule of deferred tax assets and liabilities</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net operating losses – U.S. parent:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left">Amount carried forward from prior years</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--DeferredTaxAssetsAmountCarriedForwardFromPriorYears_iI_pp0p0_c20230531__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zA1HjLP614r" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Amount carried forward from prior years">(872,137</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--DeferredTaxAssetsAmountCarriedForwardFromPriorYears_c20220531__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Amount carried forward from prior years">(859,324</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net operating losses (21% tax rate)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--OperatingLossCarryforwards_iNI_pp0p0_di_c20230531__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zRdHorOLRQHg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net operating losses (21% tax rate)">(32,815</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingLossCarryforwards_iNI_pp0p0_di_c20220531__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zzaYhwsm4jPi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net operating losses (21% tax rate)">(38,013</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued management compensation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c20230531__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued management compensation">25,200</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c20220531__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued management compensation">25,200</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Total</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_c20230531__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">(879,752</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_c20220531__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">(872,137</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company’s deferred tax assets and liabilities consist primarily of the following:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> Deferred taxes – U.S. Parent</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--DeferredTaxAssetsGross_iNI_di_c20230531__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zZDlTW8NrQle" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred tax asset">(879,752</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--DeferredTaxAssetsGross_iNI_di_c20220531__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zrDnyaK1N69h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred tax asset">(872,137</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net operating losses – Canadian subsidiary:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amount carried forward from prior years</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_ecustom--DeferredTaxAssetsAmountCarriedForwardFromPriorYears_c20230531__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amount carried forward from prior years">(31,760</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--DeferredTaxAssetsAmountCarriedForwardFromPriorYears_c20220531__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amount carried forward from prior years">(31,760</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net operating losses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--OperatingLossCarryforwards_iNI_di0_c20230531__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zqjOIxEk4axd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net operating losses">— </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLossCarryforwards_iNI_di0_c20220531__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zmNa1csIvX5c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net operating losses">— </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> Deferred taxes – Canadian subsidiary</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsGross_iNI_pp0p0_di_c20230531__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zkt4KqVYHRNa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred tax asset">(31,760</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--DeferredTaxAssetsGross_iNI_pp0p0_di_c20220531__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zsKyOqNPPc0b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred tax asset">(31,760</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsGross_iNI_di_c20230531_zFWahSPGSF4a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred tax asset">(911,512</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--DeferredTaxAssetsGross_iNI_di_c20220531_zzbnRaSyCSL1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred tax asset">(903,897</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Less: valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20230531_zFNqMvLU9lm7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: valuation allowance">911,512</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20220531_zk2oDSYh9sF1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: valuation allowance">903,897</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> Total net deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--DeferredTaxAssetsNet_iI_d0_c20230531_zw4cTGiafpUg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total net deferred tax assets">— </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--DeferredTaxAssetsNet_iI_d0_c20220531_zi933T7hlL89" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total net deferred tax assets">— </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

-872137 -859324

32815

38013

25200

-879752

-872137

879752

872137

-31760 -31760

-0

31760

911512

903897

911512

903897

7615

12813

Note 6 – Stockholders’ Deficit Common Stock Common Stock, par value of $0.001 per share; 75,000,000 shares authorized: 19,767,698 shares issued and outstanding at May 31, 2023 and 2022. Holders of Common Stock have one vote per share of Common Stock held.

0.001

75000000

19767698

Note 7 – Contingencies and Commitments From time to time the Company may be a party to litigation matters involving claims against the Company. Management believes that there are no current matters that would have a material effect on the Company’s financial position or results of operations. The Company does not have long-term commitments for equipment purchases or leases. The Company presently operates from remote employment sites.

Note 8 – Subsequent Events The Company has evaluated all subsequent events through the date these financial statements were issued and no subsequent events occurred that required disclosure.

EXCEL 35 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
7C2B8B%9 MKFOYC$GL#'H:8>\&KAQP?\Z8W"S4 =6_ >\W4$L#!!0 ( $^ 'E=@<+D\ MT , /@0 8 >&PO=V]R:W-H965T&ULK5AMJ]_WX3I(Q"I#K+ET+@ MG,.3SY88D.+NC6Y**.RO*$LS%D*WU M;,L(#G-2$NO0,)">X"C5!KW\V@L;].B.QU%*7AC(=DF"V8]'$M-#7S.U]PNO MT7K#Y05]T-OB-9D1_FW[PL1(+U7"*"%I%M$4,++J:P_F_OZN/LKG+N:R MP!D9TOBO*.2;OM;50$A6>!?S5WIX(L5\'*FWI'&6_P6'(]8U-+#<99PF!5E4 MD$3I\8B_%SZ<$""\0( % 58(%KI L J"526X%PAV0;"K)5TB. 7!J1!,ZP(! M%024>W\T*W?:QQP/>HP> )-HH29/\KARMC X2N7"FG$F[D:"QP?#Z60V_3KV M'^:!#V9S<7@.)O,9F([ \.EA\D
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
7JWHYP@( ",0 / M " 9Z* !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " !/ M@!Y798M'TS(! ",#@ &@ @ &-C0 >&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !/@!Y7M<>E16L! "-#P $P M @ 'WC@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 'P ? + % ( "3D ! end XML 36 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 37 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 38 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 52 133 1 false 17 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://preaxiahealthcare.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://preaxiahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) Sheet http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT Sheet http://preaxiahealthcare.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT Statements 6 false false R7.htm 00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 00000008 - Disclosure - Organization and Description of Business Sheet http://preaxiahealthcare.com/role/OrganizationAndDescriptionOfBusiness Organization and Description of Business Notes 8 false false R9.htm 00000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Recent Accounting Pronouncements Sheet http://preaxiahealthcare.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 10 false false R11.htm 00000011 - Disclosure - Related Party Transactions Sheet http://preaxiahealthcare.com/role/RelatedPartyTransactions Related Party Transactions Notes 11 false false R12.htm 00000012 - Disclosure - Income Taxes Sheet http://preaxiahealthcare.com/role/IncomeTaxes Income Taxes Notes 12 false false R13.htm 00000013 - Disclosure - Stockholders??? Deficit Sheet http://preaxiahealthcare.com/role/StockholdersDeficit Stockholders??? Deficit Notes 13 false false R14.htm 00000014 - Disclosure - Contingencies and Commitments Sheet http://preaxiahealthcare.com/role/ContingenciesAndCommitments Contingencies and Commitments Notes 14 false false R15.htm 00000015 - Disclosure - Subsequent Events Sheet http://preaxiahealthcare.com/role/SubsequentEvents Subsequent Events Notes 15 false false R16.htm 00000016 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Income Taxes (Tables) Sheet http://preaxiahealthcare.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://preaxiahealthcare.com/role/IncomeTaxes 17 false false R18.htm 00000018 - Disclosure - Organization and Description of Business (Details Narrative) Sheet http://preaxiahealthcare.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative Organization and Description of Business (Details Narrative) Details http://preaxiahealthcare.com/role/OrganizationAndDescriptionOfBusiness 18 false false R19.htm 00000019 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesPolicies 19 false false R20.htm 00000020 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://preaxiahealthcare.com/role/RelatedPartyTransactions 20 false false R21.htm 00000021 - Disclosure - Income Taxes (Details) Sheet http://preaxiahealthcare.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://preaxiahealthcare.com/role/IncomeTaxesTables 21 false false R22.htm 00000022 - Disclosure - Income Taxes (Details Narrative) Sheet http://preaxiahealthcare.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://preaxiahealthcare.com/role/IncomeTaxesTables 22 false false R23.htm 00000023 - Disclosure - Stockholders??? Deficit (Details Narrative) Sheet http://preaxiahealthcare.com/role/StockholdersDeficitDetailsNarrative Stockholders??? Deficit (Details Narrative) Details http://preaxiahealthcare.com/role/StockholdersDeficit 23 false false All Reports Book All Reports paxh53123.htm ex31.htm ex32.htm paxh-20230531.xsd paxh-20230531_cal.xml paxh-20230531_def.xml paxh-20230531_lab.xml paxh-20230531_pre.xml image_001.jpg image_002.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 40 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "paxh53123.htm": { "axisCustom": 0, "axisStandard": 10, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 206, "http://xbrl.sec.gov/dei/2023": 35 }, "contextCount": 52, "dts": { "calculationLink": { "local": [ "paxh-20230531_cal.xml" ] }, "definitionLink": { "local": [ "paxh-20230531_def.xml" ] }, "inline": { "local": [ "paxh53123.htm" ] }, "labelLink": { "local": [ "paxh-20230531_lab.xml" ] }, "presentationLink": { "local": [ "paxh-20230531_pre.xml" ] }, "schema": { "local": [ "paxh-20230531.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 226, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 8, "http://xbrl.sec.gov/dei/2023": 4, "total": 12 }, "keyCustom": 14, "keyStandard": 119, "memberCustom": 9, "memberStandard": 8, "nsprefix": "paxh", "nsuri": "http://preaxiahealthcare.com/20230531", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://preaxiahealthcare.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Recent Accounting Pronouncements", "menuCat": "Notes", "order": "10", "role": "http://preaxiahealthcare.com/role/RecentAccountingPronouncements", "shortName": "Recent Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "11", "role": "http://preaxiahealthcare.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "12", "role": "http://preaxiahealthcare.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Stockholders\u2019 Deficit", "menuCat": "Notes", "order": "13", "role": "http://preaxiahealthcare.com/role/StockholdersDeficit", "shortName": "Stockholders\u2019 Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Contingencies and Commitments", "menuCat": "Notes", "order": "14", "role": "http://preaxiahealthcare.com/role/ContingenciesAndCommitments", "shortName": "Contingencies and Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "15", "role": "http://preaxiahealthcare.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "16", "role": "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "17", "role": "http://preaxiahealthcare.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2005-05-302005-05-31_custom_TiempoDeMexicoLtdMember_custom_CommonStocksMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Organization and Description of Business (Details Narrative)", "menuCat": "Details", "order": "18", "role": "http://preaxiahealthcare.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative", "shortName": "Organization and Description of Business (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2005-05-302005-05-31_custom_TiempoDeMexicoLtdMember_custom_CommonStocksMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "menuCat": "Details", "order": "19", "role": "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "paxh:GrossVersusNetRevenuePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "lang": null, "name": "paxh:RevenuesFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "paxh:ConsultingFees", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Related Party Transactions (Details Narrative)", "menuCat": "Details", "order": "20", "role": "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "lang": null, "name": "us-gaap:LoansPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Income Taxes (Details)", "menuCat": "Details", "order": "21", "role": "http://preaxiahealthcare.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "lang": null, "name": "us-gaap:DeferredTaxAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLossCarryforwardsLimitationsOnUse", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Income Taxes (Details Narrative)", "menuCat": "Details", "order": "22", "role": "http://preaxiahealthcare.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income Taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLossCarryforwardsLimitationsOnUse", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "AsOf2023-05-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Stockholders\u2019 Deficit (Details Narrative)", "menuCat": "Details", "order": "23", "role": "http://preaxiahealthcare.com/role/StockholdersDeficitDetailsNarrative", "shortName": "Stockholders\u2019 Deficit (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "AsOf2023-05-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "menuCat": "Statements", "order": "4", "role": "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EarningsPerShareBasic", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)", "menuCat": "Statements", "order": "5", "role": "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EarningsPerShareBasic", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "AsOf2021-05-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT", "menuCat": "Statements", "order": "6", "role": "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "AsOf2021-05-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "7", "role": "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "lang": null, "name": "us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Organization and Description of Business", "menuCat": "Notes", "order": "8", "role": "http://preaxiahealthcare.com/role/OrganizationAndDescriptionOfBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "paxh53123.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 17, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r463", "r465", "r466" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r463", "r465", "r466" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r463", "r465", "r466" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r463", "r465", "r466" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFinStmtErrorCorrectionFlag": { "auth_ref": [ "r463", "r465", "r466", "r468" ], "lang": { "en-us": { "role": { "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction.", "label": "Document Financial Statement Error Correction [Flag]" } } }, "localname": "DocumentFinStmtErrorCorrectionFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://preaxiahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "paxh_AccountsPayableAndAccruedLiabilitiesRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accounts payable and accrued liabilities related party" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesRelatedParty", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "paxh_AccountsPayableRelatedPartyCurrent": { "auth_ref": [], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accounts payable and accrued liabilities - related party" } } }, "localname": "AccountsPayableRelatedPartyCurrent", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "paxh_AdvancesRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Advance related party" } } }, "localname": "AdvancesRelatedParty", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "paxh_CanadaDollarsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Canada Dollars [Member]" } } }, "localname": "CanadaDollarsMember", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "paxh_CommonStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stocks [Member]" } } }, "localname": "CommonStocksMember", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "domainItemType" }, "paxh_ConsultingFees": { "auth_ref": [], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Consulting", "verboseLabel": "Consulting services" } } }, "localname": "ConsultingFees", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "paxh_ConversionOfAccountsPayableAndAccruedLiabilitiesRelatedPartyToPromissoryNoteRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of Accounts payable and accrued liabilities - related party to Promissory note - related party" } } }, "localname": "ConversionOfAccountsPayableAndAccruedLiabilitiesRelatedPartyToPromissoryNoteRelatedParty", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "paxh_ConversionOfAdvancesRelatedPartyToPromissoryNoteRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of Advances - related party to Promissory note - related party" } } }, "localname": "ConversionOfAdvancesRelatedPartyToPromissoryNoteRelatedParty", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "paxh_ConvertibleNotesPayableRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable Related Party [Member]" } } }, "localname": "ConvertibleNotesPayableRelatedPartyMember", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "paxh_DeferredTaxAssetsAmountCarriedForwardFromPriorYears": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Amount carried forward from prior years" } } }, "localname": "DeferredTaxAssetsAmountCarriedForwardFromPriorYears", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "paxh_DueToRelatedPartyCurrent": { "auth_ref": [], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Advances - related party" } } }, "localname": "DueToRelatedPartyCurrent", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "paxh_GBPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "G B P [Member]" } } }, "localname": "GBPMember", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "paxh_GrossVersusNetRevenuePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Gross Versus Net Revenue" } } }, "localname": "GrossVersusNetRevenuePolicyTextBlock", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "paxh_IncomeAndExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income And Expenses [Member]" } } }, "localname": "IncomeAndExpensesMember", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "paxh_LoansPayableShareholders": { "auth_ref": [], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Loans payable - shareholders" } } }, "localname": "LoansPayableShareholders", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "paxh_ProceedsFromIssuanceOfLiabilityForUnissuedShares": { "auth_ref": [], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from the issuance of liability for unissued shares" } } }, "localname": "ProceedsFromIssuanceOfLiabilityForUnissuedShares", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "paxh_PromissoryNoteRelatedParty": { "auth_ref": [], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Promissory note - related party" } } }, "localname": "PromissoryNoteRelatedParty", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "paxh_PromissoryNoteRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Note Related Party [Member]" } } }, "localname": "PromissoryNoteRelatedPartyMember", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "paxh_RepaymentOfLoansPayableShareholder": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Repayment of loans payable - shareholder" } } }, "localname": "RepaymentOfLoansPayableShareholder", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "paxh_RevenuesFromRelatedParties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "RevenuesFromRelatedParties", "verboseLabel": "Revenue" } } }, "localname": "RevenuesFromRelatedParties", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "paxh_TiempoDeMexicoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tiempo De Mexico Ltd [Member]" } } }, "localname": "TiempoDeMexicoLtdMember", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "domainItemType" }, "paxh_TomZapatinasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tom Zapatinas [Member]" } } }, "localname": "TomZapatinasMember", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "paxh_USDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "U S D [Member]" } } }, "localname": "USDMember", "nsuri": "http://preaxiahealthcare.com/20230531", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r127", "r262", "r263", "r264", "r265", "r304", "r432", "r487", "r490", "r491" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://preaxiahealthcare.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r127", "r262", "r263", "r264", "r265", "r304", "r432", "r487", "r490", "r491" ], "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://preaxiahealthcare.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "srt_ParentCompanyMember": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "label": "Parent Company [Member]" } } }, "localname": "ParentCompanyMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://preaxiahealthcare.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "srt_SubsidiariesMember": { "auth_ref": [ "r492", "r523", "r524", "r525" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [Member]" } } }, "localname": "SubsidiariesMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://preaxiahealthcare.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r10" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r17", "r18", "r51", "r108", "r329", "r338", "r341" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r4", "r7", "r18", "r267", "r270", "r296", "r334", "r335", "r474", "r475", "r476", "r479", "r480", "r481" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r46", "r441", "r530" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r236", "r237", "r238", "r353", "r479", "r480", "r481", "r521", "r533" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r70", "r104", "r125", "r159", "r164", "r168", "r173", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r262", "r264", "r281", "r326", "r385", "r441", "r451", "r488", "r489", "r526" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r101", "r109", "r125", "r173", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r262", "r264", "r281", "r441", "r488", "r489", "r526" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r23", "r103", "r434" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r23", "r56", "r122" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, end of the period", "periodStartLabel": "Cash, beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r3", "r56" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net change in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash Investing and Financing Activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r80", "r105", "r106", "r107", "r125", "r148", "r149", "r151", "r153", "r157", "r158", "r173", "r182", "r184", "r185", "r186", "r189", "r190", "r193", "r194", "r196", "r199", "r205", "r281", "r344", "r345", "r346", "r347", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r373", "r394", "r416", "r424", "r425", "r426", "r427", "r428", "r473", "r477", "r482" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r15", "r41", "r327", "r372" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r64", "r180", "r181", "r430", "r486" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Contingencies and Commitments" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ContingenciesAndCommitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r34", "r431" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r442", "r443", "r444", "r446", "r447", "r448", "r449", "r479", "r480", "r521", "r529", "r533" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value per share", "verboseLabel": "Common stock par value per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical", "http://preaxiahealthcare.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r45", "r373" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized", "verboseLabel": "Common stock shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical", "http://preaxiahealthcare.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued", "verboseLabel": "Common stock shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical", "http://preaxiahealthcare.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r8", "r45", "r373", "r391", "r533", "r534" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding", "verboseLabel": "Common stock shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical", "http://preaxiahealthcare.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r45", "r328", "r441" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, $0.001 par value, 75,000,000 shares authorized. 19,767,698 shares issued and outstanding" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r38", "r435" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r26", "r27", "r28" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Common stock shares issuable upon conversion of debt" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r12" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible note payable - related party", "verboseLabel": "Convertible note payable related party" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets", "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r54", "r307" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r65", "r191" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Convertible note conversion price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r248" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "negatedLabel": "Total deferred tax asset" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r519" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Total net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r37", "r520" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Total" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r37", "r520" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Accrued management compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r249" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Less: valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r117", "r137", "r138", "r139", "r140", "r141", "r147", "r148", "r151", "r152", "r153", "r155", "r276", "r277", "r323", "r333", "r437" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per share - basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r117", "r137", "r138", "r139", "r140", "r141", "r148", "r151", "r152", "r153", "r155", "r276", "r277", "r323", "r333", "r437" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per share - diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r29", "r30" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r8", "r98", "r113", "r114", "r115", "r128", "r129", "r130", "r134", "r142", "r144", "r156", "r174", "r177", "r206", "r236", "r237", "r238", "r253", "r254", "r266", "r267", "r268", "r269", "r270", "r272", "r275", "r286", "r287", "r288", "r289", "r290", "r291", "r296", "r334", "r335", "r336", "r353", "r416" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r6", "r9" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignCurrencyExchangeRateTranslation1": { "auth_ref": [ "r292", "r293" ], "lang": { "en-us": { "role": { "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.", "label": "Foreign currency exchange rate translation" } } }, "localname": "ForeignCurrencyExchangeRateTranslation1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "pureItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r55", "r396" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Office and administration" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicDistributionAxis": { "auth_ref": [ "r80", "r81", "r82", "r83", "r84", "r85", "r86", "r87", "r88", "r89", "r90", "r91", "r92", "r93", "r94", "r95", "r96", "r97", "r324", "r325", "r440" ], "lang": { "en-us": { "role": { "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Axis]" } } }, "localname": "GeographicDistributionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_GeographicDistributionDomain": { "auth_ref": [ "r80", "r81", "r82", "r83", "r84", "r85", "r86", "r87", "r88", "r89", "r90", "r91", "r92", "r93", "r94", "r95", "r96", "r97", "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities." } } }, "localname": "GeographicDistributionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r53", "r125", "r159", "r163", "r167", "r169", "r173", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r281", "r439", "r488" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r0", "r63" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment of Long-lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r178", "r179", "r401" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r179", "r401" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r126", "r241", "r244", "r245", "r251", "r258", "r259", "r260", "r261", "r349" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r112", "r242", "r243", "r245", "r246", "r250", "r252", "r343" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r22", "r25" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r5" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase in accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "auth_ref": [ "r5" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase in accounts payable and accrued liabilities - related party" } } }, "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r118", "r120", "r121" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r11", "r125", "r173", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r263", "r264", "r265", "r281", "r371", "r438", "r451", "r488", "r526", "r527" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r50", "r71", "r331", "r441", "r478", "r485", "r522" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r13", "r102", "r125", "r173", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r263", "r264", "r265", "r281", "r441", "r488", "r526", "r527" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r12" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loans Payable, Current" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r14", "r35" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r119" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r119" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r56", "r57", "r58" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Cash used in operating activities", "totalLabel": "Cash flows used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r52", "r58", "r72", "r100", "r110", "r111", "r115", "r125", "r133", "r137", "r138", "r139", "r140", "r143", "r144", "r150", "r159", "r163", "r167", "r169", "r173", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r277", "r281", "r332", "r393", "r414", "r415", "r439", "r450", "r488" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss and comprehensive loss", "negatedLabel": "Net loss", "totalLabel": "Net loss and comprehensive loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit", "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r77", "r78", "r79", "r99", "r131", "r132", "r135", "r136", "r145", "r146", "r175", "r176", "r255", "r256", "r257", "r271", "r274", "r278", "r279", "r280", "r282", "r283", "r284", "r294", "r295", "r297", "r308", "r309", "r310", "r337", "r338", "r339", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/RecentAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesAndLoansPayableCurrent": { "auth_ref": [ "r10" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer.", "label": "Note payable - related party" } } }, "localname": "NotesAndLoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses [Default Label]", "totalLabel": "Total Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r159", "r163", "r167", "r169", "r439" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from Operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r36" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Net operating losses carryforwad", "negatedLabel": "Net operating losses" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/IncomeTaxesDetails", "http://preaxiahealthcare.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.", "label": "Operating loss carryforwards limitations on use" } } }, "localname": "OperatingLossCarryforwardsLimitationsOnUse", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r59", "r60", "r61", "r69" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization and Description of Business" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/OrganizationAndDescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r12", "r441" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Liability for unissued shares" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromLoans": { "auth_ref": [ "r21" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from principal payments made on loans related to operating activities.", "label": "Proceeds from Loans" } } }, "localname": "ProceedsFromLoans", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r19" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from Related Party Debt", "verboseLabel": "Advances - related party" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "Proceeds from loans payable - shareholders" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r450", "r531", "r532" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r207", "r301", "r302", "r366", "r367", "r368", "r369", "r370", "r390", "r392", "r423" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r301", "r302", "r525" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [ "r397", "r398", "r401" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r207", "r301", "r302", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r366", "r367", "r368", "r369", "r370", "r390", "r392", "r423", "r525" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r298", "r299", "r300", "r302", "r303", "r350", "r351", "r352", "r399", "r400", "r401", "r420", "r422" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r20" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayment of advances to related party", "negatedLabel": "Repayment of advances - related party" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows", "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r42", "r240", "r528" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development", "verboseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "auth_ref": [ "r1", "r2", "r42" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.", "label": "Software Development Costs" } } }, "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r47", "r67", "r330", "r337", "r341", "r348", "r374", "r441" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r98", "r128", "r129", "r130", "r134", "r142", "r144", "r174", "r177", "r236", "r237", "r238", "r253", "r254", "r266", "r268", "r269", "r272", "r275", "r334", "r336", "r353", "r533" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r395", "r433", "r436" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r116", "r125", "r160", "r161", "r162", "r165", "r166", "r170", "r171", "r172", "r173", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r281", "r325", "r488" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of deferred tax assets and liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r39", "r40", "r397", "r398", "r401" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Share issued price" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r59", "r123" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r80", "r105", "r106", "r107", "r125", "r148", "r149", "r151", "r153", "r157", "r158", "r173", "r182", "r184", "r185", "r186", "r189", "r190", "r193", "r194", "r196", "r199", "r205", "r281", "r344", "r345", "r346", "r347", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r373", "r394", "r416", "r424", "r425", "r426", "r427", "r428", "r473", "r477", "r482" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r8", "r16", "r98", "r113", "r114", "r115", "r128", "r129", "r130", "r134", "r142", "r144", "r156", "r174", "r177", "r206", "r236", "r237", "r238", "r253", "r254", "r266", "r267", "r268", "r269", "r270", "r272", "r275", "r286", "r287", "r288", "r289", "r290", "r291", "r296", "r334", "r335", "r336", "r353", "r416" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r128", "r129", "r130", "r156", "r307", "r342", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r373", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r386", "r387", "r388", "r389", "r390", "r392", "r395", "r396", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r416", "r445" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit", "http://preaxiahealthcare.com/role/IncomeTaxesDetails", "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r128", "r129", "r130", "r156", "r307", "r342", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r373", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r386", "r387", "r388", "r389", "r390", "r392", "r395", "r396", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r416", "r445" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit", "http://preaxiahealthcare.com/role/IncomeTaxesDetails", "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r44", "r45", "r67" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Shares issued for acquisition" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r45", "r48", "r49", "r62", "r375", "r391", "r417", "r418", "r441", "r451", "r478", "r485", "r522", "r533" ], "calculation": { "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "negatedLabel": "Stockholders' deficit", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total Stockholders\u2019 Deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets", "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit", "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r66", "r124", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r206", "r273", "r419", "r421", "r429" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Stockholders\u2019 Deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/StockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Disclosure:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r31", "r32", "r33", "r73", "r74", "r75", "r76" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r247" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Change in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted average number of common shares outstanding - diluted" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r147", "r153" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average number of common shares outstanding - basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://preaxiahealthcare.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482610/350-50-25-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482633/350-40-30-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org//830/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147479424/830-30-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(1))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org//205-40/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r452": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r453": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r454": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r455": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r456": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r457": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r458": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r459": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r461": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r462": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r463": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r464": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r465": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r466": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r467": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r468": { "Name": "Regulation S-K", "Number": "229", "Publisher": "SEC", "Section": "402", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r469": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r471": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r472": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org//250/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org//250/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(4)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(5)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)(i)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)(ii)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Regulation S-K (SK)", "Number": "229", "Publisher": "SEC", "Section": "1402", "Subsection": "Instruction 5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(4)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(5)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 41 0001262463-23-000074-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001262463-23-000074-xbrl.zip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end